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 Autophagy is a highly conserved pathway in which an autophagosome 
envelops cytoplasmic cargo and delivers it to the lysosome for degradation in 
order to maintain cellular homeostasis or survival in response to stress.  The 
ATG12–ATG5-ATG16L1 complex functions as an essential regulator of 
autophagosome formation.  We have discovered that DU145 prostate cancer 
(PCa) cells have a splice donor-site mutation that triggers aberrant splicing of 
ATG5 and leads to the proteasomal degradation of ATG12 and ATG16L1, thus 
completely inactivating autophagy.  We demonstrate that ATG5, ATG12, and 
ATG16L1 are coordinately degraded when not associated with the complex and 
that the ATG5-ATG16L1 interaction is essential for preventing ubiquitination and 
turnover, thereby facilitating ATG12 conjugation.  We also show that this 
	   vii	  
interaction can be disrupted through alternative ATG5 splicing and by ATG5 
genetic mutations that have been identified in human tumors.  Meta-analysis of 
available mRNA expression data indicates that ATG5 is significantly 
downregulated in PCa.  We confirmed previous reports that found prostate 
cancers have frequent deletions of the 6q21 locus containing ATG5.  However, 
mRNA expression of neighboring genes is largely unaffected, indicating ATG5 
can also be selectively downregulated though other mechanisms.  Together, this 
suggests that ATG5 functions as a tumor suppressor gene that can be 
inactivated by a variety of different mechanisms.  ATG5 is more significantly 
underexpressed than many established PCa tumor suppressor genes and is also 
underexpressed in PCa metastases compared to primary tumors.  This implies 
that ATG5 is also a tumor suppressor in advanced PCa.  ATG5 re-expression in 
ATG5-deficient DU145 PCa cells resulted in dramatic suppression of xenograft 
tumor growth, indicating that ATG5 is a functional PCa tumor suppressor gene.  
Therefore, autophagy may actually be tumor suppressive at both early and late 
stages of prostate tumorigenesis, which suggests that autophagy inhibition may 
be counterproductive for the treatment of advanced prostate cancers. 
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Chapter 1: Introduction 
 
1.1 Mechanisms of Proteolysis 
 
1.1.1 Early history of proteolysis research – Decades of groundbreaking 
research have lead to our current understanding that protein synthesis and 
proteolysis exist in equilibrium within the cells of all forms of life.  Early studies on 
DNA and the discovery of the DNA double-helix structure by James Watson and 
Francis Crick essentially established the field of molecular biology in the early 
1950s.  In the years following, several groups raced to determine how genetic 
information coded in DNA could result in the synthesis of diverse and complex 
proteins within the cell.  With the main focus of scientific interest on the 
understanding of the genetic code and protein synthesis, the importance of 
protein degradation was largely overlooked.  
Today we can appreciate that all proteins are continuously degraded and 
resynthesized and that complex mechanisms exist to ensure this degradation 
occurs in a highly controlled manner.  However, the idea that structural proteins 
unrelated to cellular metabolism were degraded was not well accepted until 
several scientists applied new technologies and used new experimental 
techniques to make significant advancements in the understanding of protein 
catabolism in the mid-1950s (Ciechanover, 2005).  The most important 
contribution was the discovery and biochemical characterization of the lysosome 
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by Christian de Duve in 1955, for which he would later win a Nobel Prize in 
Physiology or Medicine in 1974 (Bowers, 1998).  By optimizing the newly 
developed technique of cellular fractionation, de Duve discovered that certain 
fractions of rat liver homogenates contained latent acid phosphatase activity.  He 
determined that the latent activity was due to the sequestration of the active 
enzyme by a membrane barrier that could be mechanically or chemically 
disrupted.  Analyzing the activity of several acid hydrolases led de Duve to 
propose that these enzymes were contained within a novel subcellular particle 
that he termed the lysosome, due its hydrolytic properties (De Duve et al., 1955). 
Later that year, Alex Novikoff fixed Dr. de Duve’s lysosome-enriched 
fractions of rat liver and examined them with an electron microscope, a 
technology that at that time was only just beginning to see biological applications.  
Using a histochemical technique that labeled sites of acid phosphatase activity 
with electron-dense lead sulfide deposits, Novikoff and de Duve revealed the 
morphology of the lysosome, in situ, for the first time (Novikoff et al., 1956).  Dr. 
de Duve’s discovery of the lysosome was a defining moment in cell biology and 
would lead to the identification of a multitude of degradative pathways that 
converge at the lysosome. 
 
1.1.2 Discovery of autophagy – The pairing of histochemistry and electron 
microscopy (EM) became a powerful tool for characterizing the morphology of 
cellular structures that had been previously only inferred biochemically.  Early 
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studies revealed lysosomes and other membrane-bound vesicles, initially 
identified as immature or pre-lysosomes, exhibited significant functional and 
morphological diversity.  A process called heterophagy, referring to the uptake 
and degradation of extracellular material (now broadly referred to as 
endocytosis), was initially characterized by the engulfment of exogenous material 
into distinct membrane vesicles initially termed heterophagosomes.  These 
structures were shown to eventually merge with the acid phosphate-positive 
lysosomes to form hybrid phago-lysosomes, where the internalized material was 
degraded (De Duve and Wattiaux, 1966).  Currently, the term endocytosis is 
used to encompass several different cellular processes that all originate from the 
plasma membrane.  These include: phagocytosis, which is the uptake and 
extracellular material; pinocytosis, which is the uptake of extracellular fluid; and 
receptor-mediated endocytosis, which is the selective uptake of substrates that 
bind to cell-surface receptors.  Generally, these endocytic pathways terminate at 
the lysosome where the contents are degraded, although in some cases material 
can be recycled to the cell surface or secreted out of the cell (Mukherjee et al., 
1997). 
 Early EM studies also indicated that, in addition to the delivery of 
exogenous substrates to the lysosome, intracellular material could also be 
degraded upon engulfment within double-membrane bound vesicles that 
subsequently fuse with lysosomes. In 1963, Christian de Duve coined this 
process as autophagy, which is derived from Greek for “self-eating”, to contrast it 
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with the term heterophagy that defines the degradation of exogenous material 
(Ohsumi, 2014).  In 1968, Antti Arstila and Benjamin Trump eloquently illustrated 
the process of autophagy by using EM to image double and single membrane 
structures containing diverse intracellular material, including mitochondria and 
endoplasmic reticulum (ER), at various stages of degradation (Arstila and Trump, 
1968).  The double-membrane structure, called an autophagosome, lacks acid 
hydrolases necessary for proteolysis and instead serves to sequester portions of 
the cytoplasm and deliver it to the lysosome where the cargo is exposed to 
proteolytic enzymes and degraded.  It was initially determined that 
autophagosomes form de novo in the cytosol rather than originating directly from 
the plasma membrane or some other membrane vesicle, although it is now 
believed that autophagosomes form in close association with the ER and can 
receive membrane contributions from a variety of sources including the outer 
mitochondrial membrane, the plasma membrane, the ER-golgi intermediate 
compartment (ERGIC) and recycling endosomes (Shibutani and Yoshimori, 
2014).  The fusion of the autophagosome and lysosome results in the 
degradation of the both the sequestered cytoplasmic material as well as the inner 
membrane of the autophagosome, creating a single membrane structure dubbed 
the autolysosome or autophagolysosome (Klionsky, 2007) (Fig. 1.1A). 
 
1.1.3 Types of autophagy – The landmark 1966 review on lysosomes written 
by Christian de Duve and Robert Wattiaux referred to another form of autophagy 
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Figure 1.1 – Overview of autophagy pathways.  (A) Macroautophagy (herein referred to as 
autophagy) begins with the formation of a double-membrane sheet called the isolation membrane 
or the phagophore.  The phagophore/isolation membrane elongates and envelops either bulk or 
selective cytoplasmic cargo including: lipid droplets, mitochondria, ribosomes, protein aggregates, 
etc., before eventually closing to form a mature, double-membrane autophagosome.  The 
autophagosome then fuses with a lysosome where the sequestered material is degraded and can 
be recycled.  (B) Microautophagy involves bulk and selective degradation of cytoplasmic material 
by direct invagination of the lysosomal membrane.  (C) Chaperone-mediated autophagy (CMA) 
requires unfolding and translocation of proteins containing a KFERQ motif across the lysosomal 
membrane via the HSC70/LAMP-2A translocation complex.  Adapted from: Cuervo, A.M. (2011). 
Nat Rev Mol Cell Biol 12(8): 535-541.
A. B.
C.
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called microautophagy that is used to describe the direct invagination or 
sequestration of cytoplasmic material by the lysosomal membrane (De Duve and 
Wattiaux, 1966) (Fig. 1.1B).  Despite a lack of concrete evidence of its existence 
in 1966, the term microautophagy was used to differentiate the process from the 
more pronounced pathway of macroautophagy, which involves the formation of 
the autophagosome and subsequent fusion with the lysosome (Fig. 1.1A).  
Generally, the term autophagy is used to specifically refer to macroautophagy 
and this terminology will be hereafter used, unless otherwise indicated. 
To date, very little is known about microautophagy.  The most conclusive 
examples have been found in yeast where the yeast vacuole is considered 
roughly analogous to the mammalian lysosome.  Using electron microscopy, the 
yeast vacuole has been imaged invaginating and surrounding non-specific 
portions of the cytosol as well as a variety of cellular components including 
mitochondria, peroxisomes, and portions of the nucleus (Mijaljica et al., 2011).  
Microautophagy-like lysosomal structures have also been captured by EM in 
mammalian cells (de Waal et al., 1986), however the mechanism for how these 
structures form is not known.  The invagination of the endosomal membrane 
during formation of MVBs has been shown to, at times, include cytosolic proteins 
and has been described as a microautophagy-like process (Sahu et al., 2011).  
The 1980s saw the discovery of another mechanism for transporting 
specific proteins from the cytoplasm, across the lysosomal membrane and into 
the lumen of the lysosome.  This process would eventually be named chaperone-
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mediated autophagy (CMA), after the chaperone protein, heat shock cognate 
protein 70 (HSC70), was found to promote the unfolding of the target proteins 
and their translocation across the membrane via the multimerization of the 
lysosomal membrane protein, lysosome-associated membrane protein 2A 
(LAMP-2A) (Chiang et al., 1989; Cuervo and Dice, 1996) (Fig. 1.1C).  The Lys-
Phe-Glu-Arg-Gln (KFERQ) pentapeptide motif was identified as an HSC70 
binding site and was found to be both necessary and sufficient to target proteins 
for CMA, which to date has only been shown to occur in mammalian cells 
(Chiang and Dice, 1988; Chiang et al., 1989; Cuervo, 2011). 
Crosstalk has been reported between macroautophagy and CMA where 
inhibition of either form of autophagy leads to the strong activation of the 
remaining functional pathway (Cuervo and Wong, 2014).  While macroautophagy 
and CMA have distinct, non-overlapping functions, it is believed they can partially 
compensate for one another in response to cellular stress.  However, no such 
connections have been reported with microautophagy (Mijaljica et al., 2011). 
 
1.1.4 Selective autophagy – Since the observation that autophagosomes and 
autolysosomes contained a variety of intracellular material, there has been keen 
interest in determining precisely what serves as a suitable target for autophagy 
and what determines the type of sequestered cargo.  CMA is an example of a 
selective mechanism for degrading specific cytosolic proteins containing the 
KFERQ motif.  However, unlike CMA, it is generally thought that both micro and 
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macroautophagy can either selectively or non-selectively sequester intact 
cytoplasmic material of a wide range of sizes and deliver it to the lumen of the 
lysosome.  Most evidence suggests non-specific autophagy is activated as a 
survival mechanism in response to starvation conditions where bulk cytoplasmic 
material can be degraded and recycled for use in essential cellular processes.  
However, one examination of starvation-induced protein turnover by stable 
isotope labeling by amino acids in cell culture (SILAC) and mass spectrometery 
suggested some cytoplasmic components might be more preferentially degraded 
than others (Kristensen et al., 2008).  In contrast, selective autophagy is believed 
to be a homeostatic mechanism, regulating the quantities of specific organelles 
according to cellular needs and removing deleterious protein aggregates, 
damaged organelles and invading pathogens.  Usually the selective process is 
named based on the specific cargo that is enveloped and degraded such as 
aggrephagy for protein aggregates or xenophagy for pathogens.  
Organellophagy, a broad term for the autophagic degradation of organelles, 
includes, but is not limited to: mitophagy for the selective degradation of 
mitochondria, pexophagy for peroxisomes, ribophagy for ribosomes, lipophagy 
for lipid droplets, nucleophagy for portions of the nucleus, reticulophagy/ER-
phagy for the ER and even lysophagy for autophagic degradation of lysosomes 
(Okamoto, 2014) (Fig. 1.1A). 
The most studied form of selective autophagy is mitophagy, which 
eliminates excess mitochondria in times of nutrient surplus and removes 
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defective mitochondria that release reactive oxygen species (ROS) that can 
damage lipids, proteins or DNA within the cell (Murphy et al., 2011).  Mammalian 
cells have two known mechanisms of mitophagy, both of which involve 
recruitment of the mitochondrion to the autophagosome by receptor proteins that 
bind to a family of proteins called the microtubule-associated protein 1 light chain 
3 (MAP1LC3 or LC3) family, which are homologous to yeast autophagy-related 
protein 8 (Atg8) and are found exclusively on autophagosome membranes 
(Moyzis et al., 2015).   BCL2/adenovirus E1B 19kDa-interacting protein 3 
(BNIP3), NIP3-like protein X (NIX/BNIP3L) and FUN14 domain-containing protein 
1 (FUNDC1) are mitochondrial outer membrane proteins whose affinity for LC3 
family members are both positively and negatively regulated by different 
phosphorylation events that ultimately control the sequestration of the 
mitochondrion by the autophagosome (Novak et al., 2010; Liu et al., 2012; Zhu et 
al., 2013) (Fig. 1.2A and 1.2B). 
Loss of mitochondrial membrane potential leads to a second mitophagy 
mechanism initiated by the stabilization of the protein kinase, PTEN induced 
putative kinase 1 (PINK1), on the outer membrane of depolarized mitochondria.  
PINK1 recruits and phosphorylates parkin RBR E3 ubiquitin protein ligase 
(Parkin), stabilizing it on the outer membrane where it promotes the ubiquitin 
conjugation of multiple mitochondrial outer membrane proteins.  Ubiquitin is a 76-
amino acid protein that is covalently conjugated to lysine residues as a post-
translational modification and serves as a destruction signal.  The relevant 
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Figure 1.2 – Mechanisms of mitophagy.  (A)  Phosphorylation of mitochondrial outer membrane 
proteins, BNIP3 and BINP3L(NIX), increases their affinity for  the autophagosome-associated 
protein, LC3, resulting in recruitment of the mitochondrion into the autophagosome.  (B) FUNDC1 
affinity for LC3 is increased by phosphoglycerate mutase family member 5 (PGAM5)-mediated 
dephosphorylation in response to mitochondrial stress, which also leads to recruitment of the 
mitochondrion into the autophagosome.  (C)  PINK1 is stabilized on the outer membrane of 
depolarized mitochondria where it phosphorylates the E3 ligase, Parkin, stabilizing it on the outer 
membrane and stimulating its ubiquitin ligase activity.  Adapter proteins such as p62, bind 
Parkin-ubiquitinated substrates and target the mitochondrion to the autophagosome via interaction 
with LC3.  Adapted from: Moyzis et al. (2015). Am J Physiol Heart Circ Physiol 308(3): H183-192.
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ubiquitinated target proteins are not well characterized, however the adapter 
proteins sequestosome-1 (SQSTM1/p62) and neighbor of BRCA1 Gene 1 
(NBR1), are known to bind the ubiquitinated outer membrane proteins as well as 
LC3 on the autophagosomal membrane, thus incorporating the defective 
mitochondrion into the autophagosome (Okamoto, 2014) (Fig. 1.2C).  Ubiquitin, 
p62 and NBR1 have been shown to be essential for the selective autophagic 
clearance of a variety of other ubiquitinated substrates including peroxisomes, 
protein aggregates, as well as intracellular bacteria (Rogov et al., 2014).  While 
ubiquitin plays an important role in selective autophagy, it is also essential for 
another intracellular and lysosome-independent proteolysis pathway called the 
ubiquitin-proteasome system (UPS). 
 
1.1.5 Ubiquitin-proteasome (UPS) system – For many years, the only known 
location for intracellular protein degradation was the lysosome via autophagy.  
The late 1970s saw the development and use of lysosomotropic weak bases, 
such as chloroquine and ammonium chloride, which freely enter the lumen of the 
lysosome and neutralize the low pH, thus inactivating the acid hydrolase 
enzymes. These agents inhibited both heterophagy/endocytosis and autophagy, 
but surprisingly did not completely prevent intracellular proteolysis (Poole et al., 
1977).  Based on this, it was proposed that a lysosome-independent mechanism 
for intracellular proteolysis must exist. 
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In 1980, in a series of elegant biochemical studies reminiscent of De 
Duve’s fractionation experiments that led to the discovery of the lysosome, 
Avram Hershko and Aaron Ciechanover used fractionation of reticulocytes 
(immature red blood cells that lack lysosomes) and found two distinct fractions 
that contained energy-dependent proteolytic activity when combined together.  
Further characterization of one fraction would lead to the discovery of ATP-
dependent proteolysis factor-1 (APF1), which turned out to be the previously 
identified, but functionally unknown protein, ubiquitin (Wilkinson et al., 1980).  
Hershko and Ciechanover observed that ubiquitin (APF1) covalently conjugated 
to a variety of proteins and stimulated their degradation (Ciechanover, 2005). 
  Shortly after, Hershko and Ciechanover used affinity chromatography of 
immobilized ubiquitin and discovered three enzymes responsible for this covalent 
conjugation reaction: enzyme-1 (E1) that activates ubiquitin; E2, which is a 
ubiquitin-conjugating enzyme and facilitates transfer of ubiquitin to the substrate; 
and E3, which is a ubiquitin-ligase that specifically binds a target protein as well 
as the ubiquitin–E2 and catalyzes the transfer of ubiquitin to the substrate 
(Ciechanover et al., 1982; Hershko et al., 1983) (Fig. 1.3).  Hershko and 
Ciechanover would share the Nobel Prize in Chemistry in 2004 for their 
characterization of the ubiquitin system.  It is now estimated the human genome 
contains two E1 enzymes, approximately 40 E2 enzymes and more than 600 
different E3 ligases which provides remarkable substrate diversity for the 
ubiquitin conjugation reaction (Komander, 2009).   
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Figure 1.3 – Ubiquitin conjugation reaction.  Ubiquitin is activated by ATP and the 
ubiquitin-activating (E1) enzyme creating a thioester bond between its catalytic cysteine and the 
C-terminal glycine of ubiquitin.  Next, a ubiquitin-conjugating (E2) enzyme attacks the E1–ubiquitin 
thioester bond, resulting in transfer of ubiquitin to the catalytic cysteine of the E2 enzyme.  An E3 
ubiquitin-ligase enzyme then binds the E2–ubiquitin intermediate and a target protein, catalyzing 
the transfer of ubiquitin to a lysine residue on either the target protein or another ubiquitin molecule 
to form linear or branched polyubiquitin chains.  Linear polyubiquitin chains direct the target protein 
to the proteasome where ubiquitin is deconjugated and recycled and the target protein is unfolded 
and degraded.
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By the early 1990s, a large multicatalytic protease called the proteasome 
was determined to be responsible for the ATP-dependent proteolytic activity of 
the second fraction initially isolated by Hershko and Ciechanover in 1980.  The 
26S proteasome consists of a 20S core particle, a hollow cylindrical structure that 
contains proteolytic activity and two 19S regulatory particles that act like a “cap” 
to regulate protease activity by specifically recognizing ubiquitinated proteins, 
unfolding them and directing them into the pore of the core particle.  Proteasome-
associated deubiquitinases (DUBs) remove the ubiquitin tags from target proteins 
prior to their entrance into the core particle, which allows ubiquitin to be recycled 
rather than degraded along with the target protein (Ciechanover, 2005) (Fig. 1.3). 
Ubiquitin is conjugated via its C-terminal glycine residue to the ε-amino 
groups of lysine residues on target proteins as well as to lysines within other 
ubiquitin molecules.  The seven internal lysine residues of ubiquitin allow the 
formation of a variety of different isopeptide linkages that result in both linear 
polyubiquitin chains, branched ubiquitin chains or mixtures of each.  These 
chains have a variety of degradative and non-degradative functions.  Lys48 is the 
most common polyubiquitin linkage and is primarily responsible for promoting the 
proteasomal degradation of protein substrates (Komander, 2009).  Branched 
ubiquitin chains are resistant to degradation, while it is thought that all types of 
linear ubiquitin chains can promote proteasomal degradation, with the possible 
exception of Lys63-linkages (Kim et al., 2007; Komander, 2009). 
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Based on the specific length and type of the linkage, ubiquitin can also 
promote lysosomal degradation through either endocytosis or autophagy.  Lys63 
ubiquitin chains are thought to trigger the endocytosis and sorting of plasma 
membrane proteins into MVBs that ultimately fuse with lysosomes where the 
targets are degraded (Clague and Urbe, 2010). Lys63-linked ubiquitination was 
also found to promote the autophagic removal of protein aggregates, while 
monoubiquitination was shown to be sufficient to target a soluble, cytosolic 
protein to the autophagosome (Kim et al., 2008; Tan et al., 2008).  The ubiquitin 
adapter protein, p62, reportedly has higher affinity for monoubiquitin and Lys63 
polyubiquitin chains than other forms of ubiquitin, suggesting these specific forms 
may promote autophagic degradation over proteasomal degradation 
(Seibenhener et al., 2004; Long et al., 2008).  This may not always be the case 
as both Lys27 and Lys63 polyubiquitin chains have a reported role in Parkin-
mediated mitophagy (Geisler et al., 2010). Thus, while the specific functions of 
different ubiquitin linkages are not entirely clear, the unifying role of ubiquitin in 
both the proteasome and the autophagy-lysosome systems is indicative of the 
importance and the degree of crosstalk between these two intracellular 
degradation pathways. 
 
1.1.6 Crosstalk between autophagy and the UPS – Early studies 
characterizing the kinetics of protein turnover found widely differing rates of 
protein degradation (Goldberg and St John, 1976).  The UPS specializes at 
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selectively degrading short-lived, soluble, cytosolic proteins while long-lived 
proteins as well as organelles or large protein aggregates that are unable to be 
partially unfolded and enter into proteasomes can instead be selectively 
sequestered by the autophagosome and delivered to the lysosome for 
degradation.  Still, there is evidence of overlapping substrates between the two 
pathways, particularly with misfolded or aggregate-prone proteins such as alpha-
synuclein (Shaid et al., 2013). 
There are also numerous instances of cross-regulation between the two 
intracellular degradation pathways.  Most examples of crosstalk between 
autophagy and the UPS are based on observations that perturbation of one 
pathway affects the other.  Pharmacological and genetic inhibition of the 
proteasome results in the upregulation of autophagy in many different contexts, 
however the mechanisms involved in this compensation are largely unknown 
(Park and Cuervo, 2013).  In contrast, one report found that long term 
inactivation of autophagy actually impairs proteasomal degradation due to a build 
up of p62, which is normally degraded by autophagy and was proposed to be 
responsible for impeding delivery of ubiquitinated proteins to proteasomes 
(Korolchuk et al., 2009). 
Proteasomes are a reported target for starvation-induced autophagy, 
suggesting that stress-induced autophagy can directly regulate the UPS 
(Kristensen et al., 2008).  Countless examples of ubiquitination and proteasomal 
degradation of autophagy-related proteins indicate the UPS is also an important 
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regulator of autophagy.  Some examples of specific regulation of autophagy-
related proteins by ubiquitination will be discussed in more detail in the next 
section, which focuses on the molecular mechanisms regulating autophagy.  
Interestingly, autophagosome formation involves a number of ubiquitin-like  
(UBL) proteins that share similar structures and undergo multi-step conjugation 
reactions analogous to ubiquitin.  The molecular similarities between ubiquitin 
and the autophagy-related UBL proteins suggest a possible evolutionary link 
between the ubiquitin-proteasome pathway and autophagy that could potentially 
account for the extent of crosstalk between them. 
 
1.2  Molecular Mechanisms of Autophagy 
 
1.2.1 Identification of autophagy-related (ATG) genes – Electron microscopy 
was indispensible for determining the morphological characteristics of the 
forming autophagosome and its subsequent fusion with the lysosome.  For 
decades, scientific understanding of autophagy was almost entirely based on the 
early EM-based morphological descriptions of the basic autophagy pathway. Still, 
researchers had no way of quantifying the amount of actual autophagic protein 
degradation and a specific biochemical marker, such as acid phosphatase 
activity, did not exist for autophagosomes.  With no biochemical marker for 
autophagy and no knowledge of the molecular machinery involved in 
autophagosome formation, the field remained largely stagnant until the early 
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1990s when the discovery of autophagy in yeast brought the field into the 
molecular age. 
 The yeast vacuole is considered roughly analogous to the mammalian 
lysosome and contains an acidic lumen with hydrolytic enzymes.  However, the 
power of yeast genetics and the specific characteristics of the yeast vacuole 
made yeast an ideal model system for identifying the genes involved in 
autophagy.  Besides the wealth of genetic tools, one major advantage is that the 
yeast vacuole is the only organelle visible by phase contrast microscopy and it 
has a low refractive index due to its low protein content (Ohsumi, 2014).  This 
attribute led Yoshinori Ohsumi to observe that “autophagic bodies”, consisting of 
a single membrane vesicle containing cytoplasmic material, visibly accumulated 
within the vacuole of nutrient starved Saccharomyces cerevisiae containing a 
genetic deficiency in several vacuolar hydrolases (Takeshige et al., 1992).  This 
marked the first evidence of macroautophagy outside of mammalian cells.  A 
follow up EM study by Ohsumi confirmed that, similar to mammalian autophagy, 
double membrane autophagosomes form in the cytoplasm and fuse with the 
vacuole where the inner membrane and cargo, which together comprise the 
reported “autophagic bodies”, are then rapidly degraded in wild-type cells (Baba 
et al., 1995). 
The ease with which these “autophagic bodies” could be visualized 
accumulating in the vacuole upon nitrogen starvation in vacuolar hydrolase-
deficient cells made it conducive to genetic screens and would finally unveil the 
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genes involved in autophagy.  Using this approach, the first genetic screen for 
autophagy mutants was performed by Ohsumi in 1993 and yielded the first 
autophagy-related gene, apg1, which was later renamed autophagy-related 1 
(atg1) upon unification of autophagy-related gene nomenclature (Tsukada and 
Ohsumi, 1993; Klionsky et al., 2003). 
In addition to the accumulation of autophagic bodies in the vacuole, the 
atg1 mutant strain was found to be sensitive to long term nitrogen starvation.  On 
this basis, a follow up primary screen was performed based on viability following 
long-term nitrogen deprivation, followed by a secondary screen for the build up of 
autophagic bodies within the vacuole (Tsukada and Ohsumi, 1993).  This clever 
genetic approach yielded a total of 15 autophagy-related genes (atg1-15) that, 
remarkably, comprised nearly all of the genes responsible for the core autophagy 
machinery that mediates formation of the autophagosome (Table 1.1). 
Saccharomyces cerevisiae was the first eukaryotic genome to be fully 
sequenced in 1996, which greatly facilitated the cloning and identification of the 
genes identified in the Yoshinori screen. Surprisingly, only one of the identified 
autophagy-related genes was previously known at the time, sparking great 
interest in identifying the molecular functions of the autophagy-related gene 
products as well as their mammalian homologs (Ohsumi, 2014).  The core 
autophagy machinery can be divided into several functional groups that control 
distinct stages of autophagosome formation including: (1) initiation, (2) 
nucleation, (3) elongation and (4) closure.  The proteins comprising these 
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Table 1.1 – Core autophagy-related (ATG) proteins 
Yeast Mammalian
Atg1 ULK1/2
Atg13 ATG13
Atg17 FIP200 (RB1CC1) 
(functional homology)
Atg29
Atg31
Atg11
ATG101
Vps34 PIK3C3
Vps15 PIK3R4/VPS15/p150
Vps30/Atg6 Beclin 1
Atg14 ATG14L (Barkor)
Atg2 ATG2
Atg7 ATG7
Atg10 ATG10
Atg5 ATG5
Atg16 ATG16L1
Atg7 ATG7
Atg3 ATG3
Atg4 ATG4A/B/C/D
E1-like enzyme
E2-like enzyme
conjugates to Atg12
binds ATG5; involved in complex localization
Atg9 vesicle 
system
E1-like enzyme
E2-like enzyme
deconjugates Atg8/LC3 family proteins 
Atg8 LC3A/B/C; 
GABARAP/L1/L2
conjugates to PE; required for phagophore 
elongation/closure; serves as cargo adapter 
Atg12 ATG12 conjugates to Atg5; binds Atg3, catalyzes 
Atg8/LC3 conjugation
Function
interacts with Atg18
regulatory subunit; Ser/Thr protein kinase
regulatory subunit of core complex
PI-3 kinase; nucleation of phagophore
accessory subunit; directs complex to 
autophagosome formation sites
Atg18 WIPI1/2 PI3P binding protein; interacts with Atg9; recruits 
Atg12–Atg5-Atg16 complex
regulatory subunit
scaffold protein important for complex localization
forms scaffold with Atg17/Atg31
forms scaffold with Atg17/Atg29
scaffold protein
required for complex stability
Atg1/ULK1 
complex
Atg8 UBL 
conjugation 
system
Atg12 UBL 
conjugation 
system
initiation of autophagosome formation; 
recruits/activates other ATG proteins
Atg9 ATG9A/B
nucleation of the phagophore; traffics to 
phagophore via vesicles; interacts with Atg18/ 
WIPI1/2; possibly involved in membrane fusion
Beclin 1-
Vps34 
complex
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different functional groups will be highlighted below, with a particular emphasis 
on the mammalian system. 
 
1.2.2 Atg1/ULK1 complex – Atg1, and its mammalian homologs unc-51 like 
autophagy activating kinase 1 and 2 (ULK1 and ULK2), integrate several 
upstream signaling pathways and control the initiation of autophagosome 
formation.  Over 40 residues are known to be phosphorylated on ULK1 alone, 
although the functions of only a few are well characterized (Russell et al., 2014).  
Unlike the yeast Atg1 complex, the mammalian ULK1 complex has been shown 
to remain intact independent of nutrient status and includes: ATG13, an Atg13 
homolog that acts as a regulatory subunit; RB1-inducible coiled coil 1 
(RB1CC1/FIP200), a functional homolog of Atg17 thought to be a scaffold protein 
involved in complex localization; and ATG101, which is not conserved in yeast, 
but is required for complex stability (Hosokawa et al., 2009b; Mercer et al., 2009; 
Wirth et al., 2013). 
In nutrient replete conditions, the nutrient sensing complex, mammalian 
target of rapamycin complex 1 (mTORC1), associates with and phosphorylates 
ULK1 and ATG13, thereby suppressing ULK1 kinase activity and autophagy 
initiation (Ganley et al., 2009; Hosokawa et al., 2009a; Jung et al., 2009).  
Nutrient deprivation inactivates mTORC1, liberating the ULK1 complex and 
allowing it to localize to autophagosome formation sites thought to form on the 
ER in proximity to ER-mitochondria contact sites (Hamasaki et al., 2013; Wirth et 
	   22	  
al., 2013).  Active ULK1 then phosphorylates itself as well as other members of 
the ULK1 complex, although the specific functions of these later phosphorylation 
events remain unknown (Dunlop and Tee, 2013).  Active ULK1 also 
phosphorylates and inactivates mTORC1, thus creating an amplification loop for 
autophagy initiation (Dunlop et al., 2011; Jung et al., 2011) (Fig. 1.4). 
Another energy-sensing kinase, AMP-activated protein kinase (AMPK), 
which is activated by a drop in cellular energy levels dictated by the AMP:ATP 
ratio, serves as another level of control over autophagy initiation.  In addition to 
directly inhibiting mTORC1 complex activity, AMPK also positively regulates 
ULK1 activity through the phosphorylation of multiple residues (Egan et al., 2011; 
Kim et al., 2011; Shang et al., 2011).  Interestingly, active ULK1 phosphorylates 
and inactivates AMPK forming a negative feedback loop that may serve to 
prevent overactivation of ULK1 and autophagy (Loffler et al., 2011).  Thus, ULK1, 
mTORC1 and AMPK form a “kinase triad” that intricately maintains cellular 
energy levels through tight regulation of cell growth and autophagy (Dunlop and 
Tee, 2013) (Fig. 1.4).  Despite this, certain stimuli such as glucose starvation or 
ammonia treatment reportedly activate autophagy independent of ULK1 and 
ULK2 (Cheong et al., 2011; McAlpine et al., 2013). 
 Beyond its role in autophagy signaling, the exact function of the ULK1 
complex in autophagosome formation is not fully understood.  The yeast Atg1 
complex phosphorylates Atg9, which is required for Atg18 localization to the 
phagophore (Papinski et al., 2014).  Independent of its kinase activity, yeast Atg1 
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Figure 1.4 – Formation and elongation of the phagophore.  Initiation of autophagosome 
formation is controlled by the ULK1 complex which integrates AMPK and mTORC1 nutrient-related 
signaling pathways.  Both positive and negative feedback loops exist between ULK1, AMPK and 
mTORC1, ensuring tight regulation of cell growth and autophagy.  Active ULK1 phosphorylates 
AMBRA1 and Beclin 1, which activates PI3KC3 lipid kinase activity and allows the Beclin 1-PI3KC3 
complex to localize to the phagophore where it produces phosphatidylinositol 3-phosphate or PI(3)P.  
ULK1 also plays a role in the trafficking of ATG9-containing vesicles that contribute to phagophore 
nucleation.  ATG9 binds the PI(3)P effector protein, WIPI2, which recruits the 
ATG12–ATG5-ATG16L1 complex.  The ATG12–ATG5-ATG16L1 complex may also be recruited to 
the phagophore by FIP200 where it catalyzes the ubiquitin-like conjugation of LC3 to 
phosphatidylethanolamine (PE).  PE-conjugated LC3 is essential for phagophore elongation and 
closure and is involved in the recruitment of cargo into the mature autophagosome.
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is also proposed to act as a scaffold for the tethering and fusion of Atg9-
containing vesicles.  These vesicles are involved in the nucleation of the double-
membrane, cup-shaped precursor of the autophagosome called the phagophore 
(Stanley et al., 2014).  It remains unknown if the mammalian ULK1 complex 
tethers mammalian ATG9 vesicles in a similar way, although ATG9 trafficking is 
known to be ULK1-dependent (Young et al., 2006). 
The mammalian ULK1 complex, including its kinase activity, has been 
implicated in the recruitment of other ATG proteins to autophagosome formation 
sites (Chan et al., 2009).  Temporal analysis of ATG protein recruitment to 
autophagosome formation sites upon amino acid starvation indicates that ULK1 
and ATG5 are recruited simultaneously, with ATG14 following shortly thereafter 
(Koyama-Honda et al., 2013).  ATG5 is part of the ATG12–ATG5-ATG16L1 
complex that catalyzes conjugation of LC3 to the autophagosomal membrane.  
Direct binding between FIP200 and autophagy-related 16-like 1 (ATG16L1) is 
thought to be responsible for the recruitment of the ATG12–ATG5-ATG16L1 
complex to the phagophore (Nishimura et al., 2013).  On the other hand, ATG14 
associates with the class III phosphatidylinositol 3-kinase (PI3K) complex 
containing, in part, the catalytic subunit 3 (PIK3C3/VPS34), regulator subunit 4 
(p150/VPS15) as well as the Atg6 homolog and regulatory factor, Beclin 1, 
whose phosphorylation by ULK1 is required for PIK3C3 lipid kinase activity 
(Russell et al., 2013) (Fig. 1.4). 
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1.2.3 Beclin 1-PIK3C3 complex – Beclin 1, p150 (VPS15), and PIK3C3 
(VPS34) form the core complex whose function is altered by association with a 
diverse array of accessory subunit proteins (Wirth et al., 2013).  
Autophagy/Beclin 1 regulator 1 (AMBRA1) binds Beclin 1 and normally 
sequesters the complex to microtubules through interaction with the Dynein 
motor complex.  Active ULK1 phosphorylates AMBRA1, which disrupts the 
interaction with dynein and allows translocation of the Beclin 1-PIK3C3 complex 
to autophagosome formation sites (Di Bartolomeo et al., 2010).  Recently, ULK1 
phosphorylation was also reported to stabilize AMBRA1 by disrupting its 
interaction with Cullin-4, an E3 ligase that normally mediates its ubiquitination 
and proteasomal degradation (Antonioli et al., 2014). 
Interestingly, it has also been shown that active AMBRA1 promotes the 
Lys63-linked polyubiquitination of both ULK1 and Beclin 1.  Lys63-linked 
polyubiquitination of ULK1 increases ULK1 stability and kinase activity, while 
Lys63-linked polyubiquitination of Beclin 1 enhances its interaction with PIK3C3 
and stimulates its lipid kinase activity (Nazio et al., 2013; Xia et al., 2013).  Thus, 
it appears a positive feedback loop exists in which active ULK1 phosphorylates 
and liberates stable AMBRA1 which facilitates the recruitment of the Beclin 1-
PIK3C3 complex to autophagosome formation sites and results in further 
activation of both ULK1 and PIK3C3 kinase activity through Lys63-linked 
polyubiquitination.  
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The association of other subunit proteins with the core Beclin 1-PIK3C3 
complex is also heavily regulated by ubiquitin and phosphorylation post-
translational modifications.  Lys63-polyubiquitination of Beclin 1 by TNF receptor-
associated factor 6, E3 ubiquitin protein ligase (TRAF6) is proposed to activate 
autophagy by disrupting its interaction with the antiapoptotic protein, B-cell 
CLL/lymphoma 2 (Bcl-2), which normally sequesters Beclin 1 away from PIK3C3 
and suppresses its kinase activity (Shi and Kehrl, 2010; Russell et al., 2014).  
Dissociation of Bcl-2 from Beclin 1 is also enhanced upon phosphorylation of 
Beclin 1 by death-associated protein kinase 1 (DAPK) and JUN N-terminal 
kinase (JNK1) kinases (Funderburk et al., 2010).  Another Bcl-2 family member, 
myeloid cell leukemia 1 (Mcl-1), was shown to promote Beclin 1 ubiquitination 
and degradation by sequestering the ubiquitin specific peptidase 9, X-linked 
(USP9X) DUB involved in Beclin 1 stabilization (Elgendy et al., 2014).  Inhibition 
of another DUB, ubiquitin specific peptidase 13 (USP13), with the small-molecule 
inhibitor, Spautin-1, also leads to Beclin 1 ubiquitination and proteasomal 
degradation along with the rest of Beclin 1-PIK3C3 complex (Liu et al., 2011).  
Additionally, inhibition of heat shock protein 90 (HSP90) using Geldanamycin 
disrupts the HSP90-Beclin 1 interaction and results in Lys48-linked 
polyubiquitination and proteasomal turnover of Beclin 1 (Xu et al., 2011).  
Together, these findings indicate that multiple types of ubiquitination combine to 
positively and negatively regulate Beclin 1 and the Beclin 1–PIK3C3 complex. 
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Another accessory protein, ATG14 (also named Barkor), binds to the ER-
resident soluble NSF attachment protein receptor (SNARE), syntaxin-17, and 
recruits the Beclin 1-PIK3C3 complex to autophagosome formation sites thought 
to be located at ER-mitochondria contact sites (Hamasaki et al., 2013).  With the 
complex localized to the ER, PIK3C3 then phosphorylates the 3´-position of the 
inositol ring of phosphatidylinositol, forming phosphatidylinositol 3-phosphate 
(PtdIns3P or PI(3)P) that is essential for formation of the phagophore (Shibutani 
and Yoshimori, 2014). 
The exact function of PI(3)P in phagophore formation is unclear, however 
it is required for the formation of the ER-associated, Ω-like structure named the 
omegasome, which serves as a membrane cradle for the expanding phagophore.  
The PI(3)P effector protein, double FYVE domain-containing protein 1 (DFPC1), 
is recruited by PI(3)P and is used as a molecular marker for the omegasome, 
although its specific role in autophagosome formation is unknown (Axe et al., 
2008).  WD repeat domain, phosphoinositide-interacting protein 2 (WIPI2) is 
another PI(3)P effector protein that binds PI(3)P and was recently reported to 
recruit the ATG12–ATG5-ATG16L1 complex to autophagosome formation sites 
through interaction with ATG16L1 (Dooley et al., 2014) (Fig. 1.4).  ATG16L1 
interacts with WIPI2 and FIP200 through adjacent regions, however it is unclear 
how these two interactions affect one another and if the ATG12–ATG5-ATG16L1 
complex is recruited to autophagosome formation sites through two distinct 
mechanisms.  
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1.2.4 Ubiquitin-like (UBL) conjugation systems – Of the fifteen genes 
originally identified in the Yoshinori yeast genetic screen, eight turned out to be 
directly involved in two UBL conjugation reactions that are essential for the 
formation of the autophagosome (Fig. 1.5).  Atg12 and Atg8 are both UBL 
proteins that have ubiquitin-like structures and undergo multistep conjugation 
reactions (Mizushima et al., 1998a; Ichimura et al., 2000).  Similar to ubiquitin, 
the C-terminal glycine residue of ATG12 is activated by adenylation allowing it to 
form a thioester bond with the active-site cysteine residue of the E1-like enzyme, 
ATG7 (Klionsky and Schulman, 2014).  ATG12 is then transferred to the E2-like 
enzyme, ATG10, which interacts directly with ATG5 and mediates ATG12–ATG5 
conjugation independent of a known E3-like enzyme (Kaiser et al., 2012; 
Yamaguchi et al., 2012).  ATG12–ATG5 reversibly binds ATG16L1, which is 
proposed to target the ATG12–ATG5-ATG16L1 complex to the phagophore 
through interaction with FIP200 and/or WIPI2 (Nishimura et al., 2013; Dooley et 
al., 2014).  The same region of ATG12–ATG5 also interacts with tectonin beta-
propeller repeat containing 1 (TECPR1), which reportedly functions in cargo 
selection as well as during autophagosome-lysosome fusion (Ogawa et al., 2011; 
Chen et al., 2012; Kim et al., 2015). 
The ATG12–ATG5-ATG16L1 complex primarily functions as an E3-like 
enzyme to catalyze the ubiquitin-like conjugation of LC3 to 
phosphatidylethanolamine (PE) at the phagophore.  In addition, the ATG12–
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Figure 1.5 – ATG12 and LC3 ubiquitin-like conjugation reactions.  Two ubiquitin-like conjugation 
reactions are required for phagophore extension and autophagosome formation.  ATG12 and LC3 
are ubiquitin-like (UBL) proteins that share structural similarity to ubiquitin and undergo similar 
multi-step conjugation reactions.  Ubiquitin is processed by deubiquitinase (DUB) enzymes that 
release monomeric ubiquitin and expose a C-terminal glycine residue that is targeted by the 
active-site cysteine of an E1 ubiquitin-activating enzyme.  While ATG12 does not undergo 
processing, LC3 must be cleaved by ATG4 in order to expose its C-terminal glycine residue.  Both 
ATG12 and LC3 ubiquitin-like conjugation reactions share the same E1-like enzyme, ATG7.  The 
E2-like enzymes for ATG12 and LC3 conjugation are ATG10 and ATG3, respectively.  There is no 
known E3-like enzyme for catalyzing ATG12 conjugation to ATG5, although the 
ATG12–ATG5-ATG16L1 complex acts as an E3-like enzyme and catalyzes LC3 conjugation to 
phosphatidylethanolamine (PE) on the phagophore/isolation membrane.  ATG12 conjugation is 
believed to be irreversible; however, deconjugation of LC3 from the outer membrane of the 
phagophore by ATG4 is required for final maturation of the autophagosome.
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ATG5-ATG16L1 complex has been reported to both tether giant unilamellar 
vesicles and act as a flexible membrane scaffold for autophagosome formation in 
vitro (Romanov et al., 2012; Kaufmann et al., 2014).  However, no direct 
evidence of either of these functions has been found in vivo. 
Atg8/LC3 is unique amongst UBLs in that it is conjugated to the primary 
amine from the head group of the phospholipid, PE, rather than the typical ε-
amino group of a lysine residue.  Mammalian homologs of Atg8 can be classified 
into two families, each consisting of three related proteins that are similarly 
conjugated to PE. MAP1LC3A (LC3), LC3B, and LC3C are proposed to be 
essential for phagophore elongation, while GABA(A) receptor-associated protein 
(GABARAP), GABA(A) receptor-associated protein like 1 (GABARAPL1), and 
GABA(A) receptor-associated protein like 2 (GABARAPL2/GATE-16) may 
function at later stages (Weidberg et al., 2010).  While little is known about either 
group’s specific role in autophagosome formation, disruption of any of the 
upstream genes involved in Atg8/LC3 lipid-conjugation blocks formation of 
functional autophagosomes. 
Unlike Atg12, Atg8 must be cleaved by the cysteine protease Atg4 in order 
to expose the C-terminal glycine residue targeted for the ubiquitin-like 
conjugation reaction.  There are 4 mammalian Atg4 homologs (ATG4A, ATG4B, 
ATG4C and ATG4D), which may possess selectivity for certain LC3 family 
members (Li et al., 2011).  ATG7 is the E1 activating enzyme for both ATG12 
and LC3, whereas ATG3 serves as the E2-like enzyme for LC3 conjugation 
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rather than ATG10 (Hong et al., 2011; Taherbhoy et al., 2011).  It is thought that 
the ATG3–LC3 intermediate is recruited to the phagophore by ATG12 where 
binding to the ATG12–ATG5 conjugate triggers a conformational change within 
the ATG3 catalytic site that promotes the conjugation of LC3 to PE (Noda et al., 
2013; Sakoh-Nakatogawa et al., 2013).   
Atg8/LC3 is initially conjugated to both the inner and outer membranes of 
the expanding phagophore and is the only Atg protein that remains attached to 
the either membrane upon completion of autophagosome biogenesis (Klionsky 
and Schulman, 2014).   Interestingly, whereas the Atg12–Atg5 isopeptide bond is 
thought to be irreversible, Atg4-mediated deconjugation of Atg8 from the outer 
membrane of the immature autophagosome is required for full maturation and 
closure of the autophagosome for reasons that are unclear (Nair et al., 2012; Yu 
et al., 2012).  Atg8/LC3 still remains associated with the inner membrane of the 
phagophore, which allows it to serve as a platform for cargo recruitment into the 
autophagosome via adapter proteins, such as the previously mentioned p62 and 
NBR1.  These adapters bind Atg8/LC3 through short hydrophobic domains called 
Atg8-interacting motifs (AIMs) in yeast or LC3-interacting regions (LIRs) in 
mammals (Noda et al., 2010).  Proteomic analysis indicates at least 67 different 
proteins, many of which contain LIRs, interact with the six mammalian Atg8 
homologs (Behrends et al., 2010).   This includes several members of the ULK1 
and Beclin 1-PIK3C3 complexes, which suggests an additional role for Atg8 
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proteins in the recruitment of other Atg proteins involved in autophagosome 
formation (Kraft et al., 2012). 
 Since the Yoshinori screen, interest in the field of autophagy has exploded 
and significant progress has been made in our mechanistic understanding of how 
autophagy occurs and is regulated.  Still, many important questions remain, the 
largest of which relate to the role(s) of autophagy in normal physiological 
functions and its contribution to the development and progression of human 
disease. 
 
1.3 Autophagy in Physiology and Human Disease 
 
1.3.1 Neurodegeneration – The homeostatic function of autophagy is 
particularly important in the brain where the unique architecture and lack of cell 
division by postmitotic neurons exacerbates the burden of accumulating 
deleterious proteins and organelles (Wong and Cuervo, 2010).  Mice with neural-
specific genetic defects in autophagy display progressive neurodegeneration with 
features common to human neurodegenerative diseases including the 
accumulation of intracellular protein aggregates and inclusions (Hara et al., 2006; 
Komatsu et al., 2006).  Conversely, stimulation of autophagy was found to 
reduce levels of neuronal cell death in mouse models of neurodegeneration 
(Ravikumar et al., 2004; Schaeffer et al., 2012). 
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Deregulation of autophagy is associated with several human 
neurodegenerative diseases including Alzheimer’s, Huntington’s and Parkinson’s 
diseases as well as amyotrophic lateral sclerosis (ALS) (Choi et al., 2013). 
Evidence suggests the accumulation of neurofibrillary tangles (NFTs), comprised 
of hyperphosphorylated and ubiquitinated tau, correlates with the extent of 
cognitive loss in Alzheimer’s patients (Giannakopoulos et al., 2003).  Tau NFTs 
appear in several other neurodegenerative diseases, together classified as 
tauopathies, where their accumulation most likely contributes to neurotoxicity. 
Tau can be degraded by the ubiquitin-proteasome system as well as through 
macroautophagy or chaperone-mediated autophagy.  As discussed previously, 
these pathways are highly interrelated and it is not clear which pathway 
contributes more to tau degradation, although it is likely that lager aggregates of 
tau can only be degraded by macroautophagy (Lee et al., 2013).    
Mutations in PINK1 and PARK2, which encode the previously discussed 
mitophagy regulating factors PINK1 and Parkin, are highly associated with an 
autosomal recessive, early-onset form of Parkinson’s disease.  Therefore, it has 
been suspected that defects in mitophagy may lead to a buildup of damaged 
mitochondria that contribute to Parkinson’s disease.  However PINK1/PARK2 
deficient mouse models do not develop significant neurodegeneration, indicating 
that there are likely additional factors involved (Pickrell and Youle, 2015).  Lewy 
bodies are a hallmark of Parkinson’s disease and are comprised primarily of α-
synuclein aggregates that are a reported target of autophagy.  However, α-
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synuclein aggregation may also suppress macroautophagy (Winslow et al., 
2010).  Similarly, aggregated mutant huntingtin (mhtt) is a characteristic of 
Huntington’s disease and is a reported target of autophagy, yet mhtt aggregates 
also appear to interfere with the autophagic degradation of protein aggregates, 
damaged mitochondria and lipid droplets (aggrephagy, mitophagy and lipophagy) 
through an unknown mechanism (Ravikumar et al., 2002; Martinez-Vicente et al., 
2010).  The negative effects of α-synuclein and mhtt protein aggregates on 
autophagy may increase the buildup of other aggregates and damaged 
organelles, further exacerbating neurotoxicity in Parkinson’s and Huntington’s 
patients. 
1.3.2 Immunity – Autophagy also plays a key role in both innate and adaptive 
immunity.  It is activated upon infection by a wide range of cytokine and immuno-
related signaling pathways and has been shown to help protect against several 
pathogens in vivo (Choi et al., 2013).  The suppression of autophagy increases 
the susceptibility of organisms to infection in many different model systems 
(Levine et al., 2011).  Pathogens that escape into the cytoplasm are ubiquitinated 
and recruited into LC3-coated autophagosomes by adapter proteins, such as p62 
or NBR1, which bind both ubiquitin and LC3.  This version of selective autophagy 
is called xenophagy and serves to sequester intracellular bacteria, viruses and 
parasites and target them to lysosomes for destruction (Gomes and Dikic, 2014).  
The mechanism(s) for the autophagic elimination of pathogens that do not 
escape into the cytoplasm and instead remain within phagosomes or endosomes 
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is less understood.  A few possibilities have been proposed, such as the 
sequestration of pathogen-containing phagosomes/endosomes by large 
autophagosomes or their direct fusion with autophagosomes/lysosomes (Levine 
et al., 2011). 
Autophagy also has important functions in adaptive immunity where it 
participates in thymic T cell selection and the maintenance of lymphocytes, and 
is reportedly essential for major histocompatibility complex (MHC) class II antigen 
presentation (Lee et al., 2010; Mizushima and Levine, 2010).  Interestingly, 
autophagy also suppresses interferon and interleukin cytokine production, which 
limits excessive activation of the immune and inflammatory responses.  
Mutations in autophagy-related genes are associated with common inflammatory 
diseases including Crohn’s disease and lupus.  Although the mechanisms are not 
known, a disease variant of ATG16L1 (T300A) associated with Crohn’s disease 
and the several ATG5 single-nucleotide polymorphisms (SNPs) associated with 
systemic lupus erythematosus (SLE) likely disrupt the balance between the pro- 
and anti-immune functions of autophagy (Levine et al., 2011).   
 
1.3.3 Cell death – One of the most contentious aspects of autophagy is its role 
in cell death.  Historically, cell death mechanisms have been classified into two 
morphologically-defined types: apoptosis and necrosis (Liu and Levine, 2015).  
More recently, some have argued that excessive autophagy can lead to cell 
death.  Autophagic cell death was originally characterized as cell death 
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accompanied by extensive autophagic vacuolation.  However, as the molecular 
understanding of autophagy has increased, the definition has been revised to 
include the requirement that autophagic cell death must be suppressed by 
genetic or chemical inhibition of autophagy (Galluzzi et al., 2012).  This more 
stringent definition has introduced many questions as to whether autophagy is 
the actual executioner of cell death, or whether it is simply activated 
concomitantly as a survival response during cell death.  Despite this, there are 
some examples of what has currently been defined as autophagic cell death, 
particularly during Drosophila melanogaster development or in cells deficient in 
apoptosis (Liu and Levine, 2015).  Recently, a new distinct form of autophagic 
cell death was reported to be triggered by autophagy-inducing peptides, 
starvation and hypoxia-ischemia in vitro and in vivo (Liu et al., 2013b).  This form 
of autophagic cell death, termed autosis, is dependent on Na+,K+-ATPase activity 
and shows unique morphological characteristics not observed in classical 
autophagic cell death or in apoptosis/necrosis (Liu and Levine, 2015). 
 Beyond its controversial role in autophagic cell death, autophagy has well-
established molecular and functional mechanisms of crosstalk with apoptosis.  In 
response to cell death stimuli, autophagy is often activated as a cytoprotective 
response and the inhibition of this stress-induced autophagy can promote further 
apoptosis (Boya et al., 2005; Galluzzi et al., 2012).  Caspases also cleave a 
number of ATG proteins including Beclin 1, ATG4D, and ATG16L1, which likely 
suppresses the compensatory activation of autophagy during apoptosis (Betin 
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and Lane, 2009; Luo and Rubinsztein, 2010; Murthy et al., 2014).  Cleavage of 
ATG5 by calpains, another family of cell death-associated proteases, reportedly 
generates a truncated fragment that triggers mitochondrial outer-membrane 
permeabilization (MOMP) and cell death (Yousefi et al., 2006).  Numerous ATG 
proteins are cleaved by calpains in vitro, although the in vivo relevance of this is 
unknown (Norman et al., 2010).  Other autophagy-related proteins apparently 
have direct roles in apoptosis, including BNIP3/BNIP3L and unconjugated 
ATG12 (Zhang and Ney, 2009; Radoshevich et al., 2010; Haller et al., 2014).  
Thus, depending on the context, autophagy seems function in both cell survival 
and cell death, which complicates its role in many human diseases such as 
cancer. 
 
1.3.4 Tumorigenesis and tumor progression – Oncogene overexpression 
and activation are common hallmarks of cancer and have been shown to both 
positively and negatively regulate autophagy through highly complex and 
contextual mechanisms that are not well understood (Galluzzi et al., 2015).  The 
homeostatic function of selective autophagy, which occurs at basal levels in all 
cell types, is critical for the suppression of malignant transformation and 
tumorigenesis.  The first evidence of this was the finding that mice possessing a 
heterozygous deletion of Becn1, the gene encoding for Beclin 1, spontaneously 
developed a variety of malignancies in the blood, liver and lungs (Qu et al., 2003; 
Yue et al., 2003).  Mosaic deletion of Atg5 or liver specific deletion of Atg7 also 
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resulted in the development of liver tumors in mice; however, these tumors 
remained benign and did not progress into carcinomas (Takamura et al., 2011).  
This was the first indication that stress-induced autophagy, which can be 
activated by stressors within the tumor microenvironment or during invasion and 
metastasis, may be required for tumor cell survival or progression.  In both V-raf 
murine sarcoma viral oncogene homolog B (BRAFV600E) and Kristen rat sarcoma 
viral oncogene homolog (KRASG12D)-driven murine lung cancer models, knockout 
of Atg7 or Atg5 accelerated tumor initiation.  However in both models, the 
acceleration in tumor formation was coupled with a reduction in tumor 
progression into malignancy, resulting in increased mouse survival (Strohecker et 
al., 2013; Rao et al., 2014).  Similar results were found with KRASG12D-driven 
murine pancreatic cancer models (Rosenfeldt et al., 2013; Yang et al., 2014).  
Based on these mouse model findings, the current hypothesis is that autophagy 
plays a dual-role in tumorigenesis, where selective autophagy suppresses early 
stages of tumor initiation, while stress-induced autophagy promotes tumor 
survival and progression at later stages.  However, deletion of Atg5 or Atg7 had 
completely opposite effects on pancreatic tumor progression depending on the 
status of Trp53 (Rosenfeldt et al., 2013), which indicates that there are important 
contextual aspects that affect the function of autophagy in cancer. 
 There are several potential mechanisms for the tumor suppressive 
function(s) of autophagy.  In addition to its controversial role in autophagic cell 
death, autophagy has been increasingly implicated in the initiation of oncogene-
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induced senescence and cell death (Young et al., 2009; Liu et al., 2013a).  
Another potential tumor suppressive mechanism is the mitophagic removal of 
dysfunctional mitochondria that can produce ROS, since ROS damage DNA, 
increase genomic instability and promote malignant transformation (Lorin et al., 
2013; Sabharwal and Schumacker, 2014).  Autophagy also directly targets 
proteins that can promote oncogenesis including p62, mutant tumor protein p53 
(p53), and the oncogenic fusion proteins: breakpoint cluster region–c-Abl 
oncogene 1-ABL proto-oncogene 1 (BCR–ABL1), and promyelocytic leuikemia–
retinoic acid receptor, alpha (PML–RARA), which result from chromosomal 
translocations (Galluzzi et al., 2015).  Finally, autophagy may function to 
suppress tumorigenesis through xenophagic elimination of potentially oncogenic 
bacteria and viruses and by the suppression of excessive or chronic 
inflammation, which are known to promote tumorigenesis (Hanahan and 
Weinberg, 2011) (Fig. 1.6). 
 In contrast, the stress-induced cell survival function of autophagy is 
thought to promote tumor progression once malignant transformation occurs.  
Conditions commonly found within the tumor microenvironment, such as hypoxia, 
low pH, and high levels of oxidative and metabolic stress are all known inducers 
of autophagy.  In the absence of an autophagic response, these conditions can 
promote tumor cell death and limit tumor progression (Galluzzi et al., 2015).  
Autophagy also suppresses anoikis, which is cell death resulting from a loss of 
cell adhesion, which occurs during the epithelial-mesenchymal transition (EMT) 
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Figure 1.6 – Role of autophagy in tumor initiation, progression and therapy.  Preclinical data 
suggest autophagy plays a highly contextual role in cancer depending on the tumor type, stage and 
genetic background.  Autophagy is generally thought to suppress early tumorigenesis by eliminating 
sources of reactive oxygen species (ROS), such as damaged mitochondria, that can promote DNA 
damage and lead to malignant transformation.  Autophagy can also directly eliminate oncogenic 
factors including p62, mutant p53, viruses, etc.  Although not well understood, autophagy has been 
implicated in both cell death and oncogene-induced senescence, which may prevent the expansion 
of transformed cells.  Autophagy also plays an important role in the suppression of chronic 
inflammation that can  promote tumor growth and progression.  Once a tumor is formed, however, it 
is thought that stress-induced autophagy becomes tumor promotive.  The harsh conditions often 
found in the tumor microenvironment including low pH, low nutrient and oxygen levels, and high 
levels of ROS are all known to activate autophagy.  Autophagy may also help cells survive 
detachment from the extracellular matrix (ECM) during invasion and metastasis.  Chemotherapeutic 
agents elicit autophagy-dependent survival responses and autophagy may also help maintain 
dormant, quiescent tumor subpopulations in response to cancer therapies that can potentialy lead to 
tumor recurrence.  These tumor promotive aspects make autophagy a highly attractive therapeutic 
target.  Adapted from: Lorin et al. (2013). Semin Cancer Biol 23(5): 361-379.
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and is thought to precede tumor cell invasion and metastasis (Avivar-Valderas et 
al., 2013; Cai et al., 2014) (Fig. 1.6).  Thus, since tumor invasion and metastasis 
are ultimately responsible for cancer mortality, the prosurvival function of 
autophagy has become a major point of interest for potential therapeutic 
intervention. 
 
1.3.5 Cancer therapy – In addition to autophagy activation during invasion and 
metastasis, tumor cells treated with radiation and chemotherapeutic agents also 
activate autophagy as a cytoprotective response (Gewirtz, 2014).  In contrast to 
its potential role in oncogene-induced senescence, autophagy may also play a 
role in maintaining tumor cell quiescence and dormancy (Lu et al., 2008).  
Interestingly, autophagy was recently found to sustain a dormant, cancer stem 
cell–like population upon oncogenic KRAS ablation in a murine pancreatic cancer 
model (Viale et al., 2014).  This suggests that autophagy may be essential for the 
survival of chemoresistant tumor cells that are responsible for cancer recurrence 
(Fig. 1.6).  These observations have become the basis for numerous ongoing 
clinical trials in which autophagy inhibitors (primarily hydroxychloroquine) have 
been used in an attempt to sensitize tumor cells to chemotherapies and reduce 
the incidence of tumor recurrence (Jiang and Mizushima, 2014). 
Despite the promise of these current clinical trials, expectations are 
somewhat tempered due to a number of outstanding problems for which we 
currently lack understanding.  At a basic level, it is not entirely clear which types 
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of tumors are susceptible to sensitization by autophagy inhibitors.  One recent 
examination of breast cancer cells with different subtypes found that the 
transcription factor, signal transducer and activator of transcription 3 (STAT3), 
imparted sensitivity to autophagy inhibition (Maycotte et al., 2014).  Identifying 
the specific tumor types most likely to be sensitized by autophagy inhibitors is a 
crucial task for the future.  Hydroxychloroquine, a derivative of chloroquine, is a 
lysosomotropic agent that neutralizes the pH of the lysosome and inactivates the 
acid hydrolases responsible for lysosomal degradation, therefore blocking both 
autophagic and lysosomal degradation.  A recent study suggests that the tumor 
suppressive effects of chloroquine are autophagy-independent, casting some 
doubt onto the efficacy of autophagy inhibition, per se, in combination with 
chemotherapy (Maes et al., 2014).  Still, extensive preclinical data suggest that 
autophagy plays an important, though context-dependent role, in tumor 
formation, progression, and therapeutic responses.  Our increased 
understanding of the mechanisms involved in autophagy will help in the design of 
more targeted and effective approaches to treating cancer. 
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Chapter 2: Materials and Methods 
 
2.1 Expression constructs – The lentiviral FG9-Puro vector, as well as 
pRSV-REV, pRRE and pHCMV-G 3rd generation lentivirus packaging vectors 
were kindly provided by Dr. Casey Wright (University of Texas at Austin, Austin, 
TX).  FG9-Puro-FLAG was designed by knocking out the XbaI site downstream 
of the multiple cloning site (MCS) by site-directed mutagenesis followed by oligo 
cloning a FLAG tag into the XbaI/BamHI sites just upstream of the MCS.  Human 
ATG5 cDNA was obtained by reverse transcriptase-PCR (RT-PCR) of mRNA 
isolated from PC-3 PCa cells.  Murine Atg5 cDNA was purchased from Addgene 
(#13095; Cambridge, MA).  Both hATG5 and mAtg5 were then cloned into the 
BamHI/NotI sites of FG9-Puro-FLAG.  Site directed mutagenesis was used to 
introduce the K130R mutation into both human and mouse versions.   
The psPAX2 2nd generation lentivirus packaging vector was purchased 
from Addgene (#12260).  ATG5 short hairpin RNA (shRNA) #1 (V3LHS_301134; 
sense 5´-CCA ACT TGT TTC ACG CTA T-3´); ATG5 shRNA #2 (V2LHS_67978; 
sense 5´-CCC ATC TTT CCT TAA CGA A-3´); and a non-silencing control 
(#RHS4346; sense 5´-CTC GCT TGG GCG AGA GTA A-3´) in the pGIPZ shRNA 
lentiviral vector were obtained from the shRNA and ORFeome Core Facility at 
the University of Texas MD Anderson Cancer Center. 
ATG5 cDNA cloned into the pLOC lentiviral vector was also obtained from 
the shRNA and ORFeome Core Facility.  ATG5 pLOC-STOP was created by 
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reintroduction of the endogenous stop codon in order to eliminate extra 
downstream nucleotides resulting from the “open” ORF configuration.  K130R, all 
structure-directed, and most of the cancer-associated mutations were introduced 
by site-directed mutagenesis.  For those mutations predicted to result in N-
terminal deletions, only the portion of ATG5 predicted to be translated was 
amplified by PCR and cloned into BamHI/NheI sites of pLOC.  pLOC-HA was 
designed by amplifying ATG5 by PCR with the HA-tag sequence contained within 
the reverse primer (forward: 5´-GGA GGA TCC ATG ACA GAT GAC AAA GAT 
GTG CTT-3´; reverse: 5´-ATA GCG CGC CTC AAG CAT AAT CTG GAA CAT 
CAT ATG GAT AGC TAG CAT CTG TTG GCT GTG-3´) and cloning it into the 
BamHI/AscI sites of pLOC.  The predicted coding sequence of each ATG5 splice 
variant was amplified by PCR and cloned into the BamHI/NheI sites of pLOC-HA. 
Incomplete cDNAs for ATG16L1 (ORF50-54133 and HsCD00400231) 
were purchased from the CCSB Human ORFeome Collection (Boston, MA).  The 
C-terminal portion of ATG16L1 from was amplified from ORF50-54133 template 
by PCR (forward: 5´-CCG GAA TTC CAG AGA CAG GCG TTC GAG GAG-3´; 
reverse: 5´-AAT GCG GCC GCG TAC TGT GCC CAC AGC ACA GC-3´) and 
cloned into the EcoRI/NotI sites of pGEX-4T-1 vector.  Next, full-length ATG16L1 
was assembled by PCR amplifying the N-terminus from HsCD00400231 
(forward: 5´-CCG GAA TTC CAG AGA CAG GCG TTC GAG GAG-3´; reverse: 
5´-AGA AGA TCT GAC TTT TCC AGC AAT TTG TTA TAC-3´) and cloning it into 
the EcoRI/BglII sites of the previously mentioned ATG16L1 C-terminal construct.  
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Once assembled in pGEX-4T-1, the internal BamHI site was removed by site 
directed mutagenesis and full-length ATG16L1, and ATG16L1 with an N-terminal 
deletion (Δ-39), were amplified by PCR and cloned into the BamHI/NheI sites of 
pLOC-HA. 
 
2.2 Reagents and antibodies – TransIT®-2020 Transfection Reagent 
(#MIR5400) was purchased from Thermo Fisher Scientific (Waltham, MA).  
MG132 (#S2619) was purchased from Selleck Chemicals (Houston, TX).  
Bafilomycin A1 (Baf A1, #1334) was purchased from Tocris Bioscience (Bristol, 
UK).  L-valine [14C(U)] (#MC-277) was purchased from Moravek Biochemicals, 
(Brea, CA).  Cold L-Valine (#V0500) and 3-methyladenine (3-MA; #M2981) were 
purchased from Sigma-Aldrich (St. Louis, MO). 
Antibodies for β-actin (#4967), AMBRA1 (#12250), ATG3 (#3415), ATG5 
(#2630, C-terminal, human-specific), ATG7 (#2631), ATG12 (D88H11, #4180), 
ATG13 (#6940), ATG16L1 (D6D5, #8089), ATG101 (#8764), Beclin 1 (#3738), 
LC3B (#2775), p62/SQSTM1 (#5114), TECPR1 (D6C10, #8097), and ULK1 
(D8H5, #9084) were purchased from Cell Signaling Technology (Danvers, MA).  
N-terminal mouse-reactive ATG5 antibody (#NB110-53818) was purchased from 
Novus Biologicals (Littleton, CO).  FIP200/RB1CC1 antibody was purchased 
from Proteintech Group (Chicago, IL).  PIK3C3/Vps34 antibody (#38-2100) was 
purchased from Life Technologies (Grand Island, NY).  β-Tubulin antibody (E7) 
was purchased from the Developmental Studies Hybridoma Bank (DSHB) (Iowa 
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City, IA).  HA antibody (HA.11 Clone 16B12; #MMS-101P) was purchased from 
Covance (Princeton, NJ).  FLAG antibody (M2; #F1804) was purchased from 
Sigma-Aldrich (St. Louis, MO). 
 
2.3 Cell lines and culture conditions – DU145 PCa cells (HTB-81) were 
purchased from American Type Culture Collection (ATCC) (Manassas, VA).  PC-
3 and LNCaP PCa cells were kindly provided by Dr. Dean Tang (The University 
of Texas MD Anderson Cancer Center-Science Park, Smithville, TX).  PCa cells 
were grown in RPMI-1640, supplemented with 10% fetal bovine serum (FBS), 
and 2mM L-glutamine.  A549 lung cancer cells were kindly provided by Dr. 
Gerald Cohen (University of Liverpool, Liverpool, UK).  A549 cells were grown in 
DMEM supplemented with 10% FBS and 4mM L-glutamine.  ATG16L1+/+ WT and 
ATG16-/- HCT116 colorectal cancer cells were kindly provided by Dr. David 
Boone (Indiana University School of Medicine-South Bend, South Bend, IN) 
(Messer et al., 2013).  HCT116 cells were grown in McCoy’s 5A media 
supplemented with 10% FBS and 2 mM L-glutamine.  All cancer cells were 
maintained at 37°C in humidified air containing 5% CO2 and routinely passaged 
every 3 days. 
Atg5+/+ WT and Atg5-/- mouse embryonic fibroblasts (MEFs) were kindly 
provided by Dr. Noboru Mizushima (University of Tokyo, Tokyo, JP) (Kuma et al., 
2004).  Atg12+/+ and Atg12-/- MEFs were kindly provided by Dr. Jayanta Debnath 
(University of California-San Francisco, San Francisco, CA) (Malhotra et al., 
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2015).  Atg16L1+/+ and Atg16L1Δ/Δ MEFs were kindly provided by Dr. Shizuo 
Akira (Osaka University, Osaka, JP)(Saitoh et al., 2008).  These MEFs were 
grown in DMEM supplemented with 10% FBS and 4mM L-glutamine at 37°C in 
humidified air containing 5% CO2 and were routinely passaged every 3 days.  
Atg3+/+, Atg3-/-, Atg7+/+, and Atg7-/- MEFs were kindly provided by Dr. Masaaki 
Komatsu (Tokyo Metropolitan Institute of Medical Science, Tokyo, JP)(Komatsu 
et al., 2005; Sou et al., 2008).  These MEFs were grown the same conditions as 
the others except they were maintained at 32.5°C. 
 
2.4 Lentiviral transduction and stable cell line generation – Human 
embryonic kidney cells (HEK293T) were kindly provided by Dr. Casey Wright 
(University of Texas at Austin, Austin, TX).  Cells were grown in DMEM media 
supplemented by 10% FBS and 4 mM L-glutamine 37°C in humidified air 
containing 5% CO2 and were routinely passaged every 3 days.  To start, 2.5x106 
low-passage number HEK293T cells were plated in a 10 cm plate.  The next day, 
cells were transfected with a lentiviral vector along with packaging plasmids (15 
µg total DNA with 45 µl TransIT-2020 transfection reagent) in a total of 7 mL of 
media.  For 2nd generation lentiviral packaging, psPAX2 and pHCMV-G 
packaging vectors were used.  For 3rd generation lentiviral packaging: pRSV-
REV, pRRE and pHCMV-G packaging vectors were used.  ~48 hours later the 
media was collected in a 10 mL syringe and 7 µL of sterile polybrene (5 µg/µL) 
was added and mixed.  Collected media was filtered through a 0.45 µm PVDF 
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syringe filter into two wells of a 6-well plate. 3x105 target cells in 1mL of culture 
media were then immediately added to each well and incubated until confluent.  
For pLOC or pGIPZ vectors, successful transduction was verified by GFP 
expression.  For FG9 vectors, transduced cells were cultured in media containing 
2 µg/µL puromycin dihydrochloride (#540411; EMD Millipore, Billerica, MA) for 7 
days. 
 
2.5 Western blot analysis – After various treatments, 1.5x106 cells in a 6 cm 
plate were collected and lysed in 100 µL RIPA Buffer (50 mM Tris-HCl pH 7.4, 
150 mM NaCl, 1% NP-40, 1% Na-deoxycholate, 0.1% SDS and proteasome 
inhibitors).  Lysates were stored at -20°C until ready for use.  For SDS-PAGE, 
lysates were sonicated, centrifuged and the soluble fraction was collected, 
quantified by Bradford assay and normalized to equal concentrations.  6X 
Laemmli buffer (375 mM Tris pH 6.8, 12% SDS, 50% glycerol, 10%  β-
mercaptoethanol, 0.06% bromophenol blue) added to the lysates and boiled for 5 
min.  50 ug of total lysate was added to each lane of 10% or 15% polyacrylamide 
gels.  SDS-PAGE was run at 125 V for 90 min prior to transfer onto nitrocellulose 
or PVDF membrane for 2 h at 90 V.  Membranes were blocked in 5% non-fat milk 
in TBS-T (Tris-buffered saline + 0.1% Tween-20) for 1 h at room temperature.  
Membranes were washed twice in TBS-T for 5 min and incubated in primary 
antibody overnight with constant agitation.  The next day membranes were 
washed twice with TBS-T and incubated in secondary antibody diluted 1:2000 in 
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5% milk in TBST-T for 1 h at room temperature.  Blots were then washed twice 
with TBS-T and visualized on x-ray film using enhanced chemiluminescence 
(Perkin Elmer-Lighting Plus or Pierce ECL2). 
 
2.6 Transmission electron microscopy – Cells were fixed in Karnovsky’s 
fixative (0.2 M sodium cacodylate (Na-Caco), 2.5% glutaraldehyde, and 2% 
paraformaldehyde) for 1 h, post-fixed with osmium-ferrocyanide (2% OsO4, 2% 
ferrocyanide in 0.2 M Na-Caco buffer) for 1-2 h, and then stained with 2% 
aqueous uranyl acetate for 1 h.  Cells were then dehydrated stepwise and 
embedded in epoxy resin.  Sectioning, imaging and data interpretation was 
performed by Dr. Dwight Romanovicz (University of Texas at Austin, Austin, TX) 
or Dr. David Dinsdale (University of Leicester, Leicester, UK).   
 
2.7 Long-lived protein turnover assay – 0.5x106-1.0x106 cells were plated 
in duplicate in 6-well plates for each time point, including time 0 h and cold 
controls.  The next day the media was replaced with fresh media containing 0.2 
µCi/mL L-valine [14C(U)] (MC-277, Moravek Biochemicals, Brea, CA).  Cold 
control cells received cold L-valine instead.  Cells were incubated overnight then 
the hot media was removed and cells were washed 3X with Hank’s buffered 
saline solution (HBSS).  Cells were then incubated for 1 h with fresh media 
containing 10 mM cold L-valine.  Time 0 h controls were then harvested and 
precipitated with 10% Trichloroacetic Acid (TCA).  The cells were spun down and 
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the soluble fraction was removed and collected.  The insoluble fraction was then 
dissolved in 1 mL 0.2 M NaOH.  100 µL of each fraction was added to 5mL of 
scintillation cocktail (Biocount cocktail, RPI Corp #111182) and measured for 
counts per minute (cpm) using a scintillation counter.  The total cpms were 
calculated by multiplying the measured cpm by the 1:10 dilution factor.  The two 
fractions were added together to calculate the total radioactivity (T). 
In the meantime, the rest of the cells were washed twice with HBSS and 
then either incubated with 2 mL of complete media containing 10 mM cold L-
valine + dimethyl sulfoxide (DMSO), 10 mM cold-L-Valine + 3-MA (10 mM), 
HBSS + DMSO or HBSS + 3-MA (10 mM).  At each time point 50 µL of media 
from each well was collected and TCA precipitated with 50 µL of 20% TCA.  The 
cpm of the soluble fraction was then measured as stated previously and the total 
radioactivity released into the media (M) was calculated by multiplying the 
measured cpm by the 1:40 dilution factor.  This was repeated at each time point.  
The fraction of protein degradation (D) was calculated as a function of the 
fraction of the total radioactivity released into the media.  To calculate this, we 
took the corrected cpm from each time point (M) and divided it by the total 
radioactivity (T).  To isolate degradation specifically related to autophagy from 
other forms of protein turnover, we subtracted the fraction of protein degradation 
in the presence of the autophagy inhibitor 3-MA (D3-MA) from the fraction of 
protein degradation from DMSO treated cells (DDMSO).  The same calculations 
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were made for HBSS+DMSO and HBSS+3-MA.  This results in the % of 3-MA 
sensitive protein degradation. 
(M)/(T)=(D) 
(DDMSO)-(D3-MA) x100 = % of 3-MA sensitive protein degradation 
 
2.8 Reverse transcriptase-PCR and genomic PCR.  mRNA was isolated 
from DU145 PCa cells using the Qiagen RNeasy Kit (#74104).  cDNA was 
synthesized using 1 µg of mRNA template and the Promega Reverse 
Transcription System (#A3500) in 20 µL total volume. cDNA (2 µL)was then used 
as template to amplify ATG5 transcripts by PCR (forward: 5´-GGA GGA TCC 
ATG ACA GAT GAC AAA GAT GTG CTT-3´; reverse: 5´-GCT GCT AGC TCA 
ATC TGT TGG CTG TGG GAT G-3´).  PCR products were separated on an 
agarose gel, excised and purified and then cloned into the pGEM-T easy vector 
(Promega, Madison, WI).  Clones were sequenced and identified splice variants 
were then cloned into the BamHI/NheI enzyme sites of pLOC-HA. 
 Genomic DNA from DU145 PCa cells was isolated using the Promega 
Wizard® Genomic DNA Purification Kit (#A1120) and used as a template for 
PCR using primers flanking ATG5 exon 6 (forward: 5´-CAG AAA CTT CTA GAG 
GGA TAT TTA-3´; reverse: 5´-ACC GTT TAG TTA CTA TGC AGA CAA-3´).  The 
PCR product was cloned into pGEM-T easy vector and several clones were 
sequenced to verify the genomic sequence. 
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2.9 Bioinformatic analyses – ATG5 splice region and nonsynonymous 
coding sequence mutations identified in human tumor samples were compiled 
from the Catalogue of Somatic Mutations in Cancer (COSMIC: 
http://cancer.sanger.ac.uk/cosmic), the cBIOPortal for Cancer Genomics 
(http://www.cbioportal.org), and the International Cancer Genome Consortium 
(ICGC: https://icgc.org).  Original sequencing and copy number information 
comes from ICGC, the Cancer Genome Atlas (TCGA: https://tcga-
data.nci.nih.gov/tcga/) and other publically available tumor datasets.  cBioPortal 
was also used to compare mutation and copy number alteration frequency in 
TCGA datasets.  We used The Oncomine™ Platform (Life Technologies, Ann 
Arbor, MI) for analysis and visualization of copy number alterations and mRNA 
expression in multiple PCa datasets.  Oncomine™ ranks genes based on the 
significance of copy number or mRNA expression alterations and performs 
student’s t-tests across all data sets to determine statistical significance. 
 
2.10 In vitro cell proliferation assay – DU145 PCa cells stably expressing an 
empty vector (EV) or FLAG-ATG5, were transduced with lentivirus expressing 
firefly luciferase fused to mCherry.  Successful transduction of luciferase was 
verified by mCherry fluorescence.  1x104 EV and FLAG-ATG5 expressing cells 
were plated in duplicate into 6-well plates.  Once per day, cells were collected in 
a total volume of 1 mL and the number of cells in 100 µL was measured daily 
using flow cytometry (Accuri™ C6 Cytometer, BD Biosciences, San Jose, CA).  
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The total number of cells in each group was then calculated based on the 1:10 
dilution factor. 
 
2.11 PCa xenograft tumor model – The same cell lines described above were 
used for a PCa xenograft tumor model.  For each group, 1x104 cells in 50 µL of 
RPMI media containing 50% Matrigel™ Membrane Matrix (Corning, #356237) 
were subcutaneously injected into each dorsal flank of 5 female NOD/SCID mice 
aged between 6 and 8 weeks.  Tumor growth was monitored weekly using the 
IVIS Spectrum in vivo imaging system.  Mice were intraperitoneally injected with 
100 µl of D-Luciferin (15 µg/µL; 50-853-139 Thermo Fisher Scientific, Waltham, 
MA) and measured for luminescence after 10-15 min with the IVIS Spectrum.  
Tumor growth was taken to be a function of the average radiance 
(photons/s/cm2/sr).  After 7 weeks, mice were sacrificed and the tumors were 
harvested, weighed and photographed.  Tumor lysates were also prepared and 
immunoblotted for ATG5, ATG12, ATG16L1 and p62. 
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Chapter 3: Regulation of ATG12–ATG5-ATG16L1 complex 
formation 
 
3.1 Introduction 
 
 Macroautophagy, herein referred to as autophagy, is the most extensively 
understood form of autophagy.  It requires the formation of a double-membrane 
autophagosome, which envelops cytoplasmic material prior to fusing with the 
lysosome where the inner membrane and the sequestered cargo are degraded.  
Autophagosomes can non-selectively sequester bulk cytoplasmic cargo, 
although it is increasingly clear that soluble proteins, protein aggregates, 
invading pathogens and a wide variety of organelles can be selectively degraded 
as well (Okamoto, 2014). 
Over thirty ATG genes have been identified, most of which are essential 
for the intricate process of autophagosome formation.  The ULK1 complex 
controls the initiation of autophagosome formation by integrating upstream AMPK 
and mTORC1 nutrient-related signaling pathways (Russell et al., 2014).  Active 
ULK1 phosphorylates several subunits of the Beclin 1-PIK3C3 complex, which 
promotes the activation of PIK3C3 lipid kinase activity and the translocation of 
the complex to autophagosome formation sites on the ER, via the accessory 
subunit ATG14 (Shibutani and Yoshimori, 2014).  At the ER, active PIK3C3 
phosphorylates the 3´-position of the inositol ring of phosphatidylinositol, forming 
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PI(3)P.  PI(3)P is essential for formation of the omegasome that serves as a 
cradle for the double-membrane precursor of the autophagosome, known as the 
phagophore or isolation membrane (Shibutani and Yoshimori, 2014).  The PI(3)P 
effector protein, WIPI2, was recently shown to recruit the ATG12–ATG5-
ATG16L1 complex to the phagophore through an interaction with ATG16L1 
(Dooley et al., 2014).  FIP200, a scaffold protein of the ULK1 complex, interacts 
with ATG16L1 at an adjacent region and may also be involved in recruitment of 
the complex (Gammoh et al., 2013; Nishimura et al., 2013).   
Formation of the ATG12–ATG5-ATG16L1 complex requires a ubiquitin-
like (UBL) conjugation reaction involving the UBL protein, ATG12.  Similar to 
ubiquitin conjugation, this reaction requires an E1-like activating enzyme (ATG7) 
and an E2-like conjugating enzyme (ATG10), which together mediate the 
covalent conjugation of the C-terminal glycine of ATG12 to Lys-130 of ATG5 
(Mizushima et al., 1998b).  There is no known E3-like enzyme that catalyzes the 
conjugation reaction per se and almost nothing is known about how the reaction 
is regulated (Fig. 1.5).  Through its interaction with FIP200 and/or WIPI2, 
ATG16L1 is thought to localize the ATG12–ATG5 conjugate to the phagophore 
where it functions as an E3-like enzyme for another ubiquitin-like reaction 
involving LC3.  LC3 is activated by ATG7 and transferred to the E2-like enzyme 
ATG3, which is then recruited to the phagophore by ATG12.  ATG12–ATG5 
binding to ATG3 induces a conformational change in ATG3 that triggers 
conjugation of LC3 to PE, which is essential for phagophore extension and 
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formation of the autophagosome (Noda et al., 2013; Otomo et al., 2013; Sakoh-
Nakatogawa et al., 2013).  PE-conjugated LC3 has a well-established role in the 
recruitment of cargo into the autophagosome (Rogov et al., 2014).  It has also 
been shown to promote membrane fusion with the phagophore and may also 
serve as a membrane scaffold together with the ATG12–ATG5-ATG16L1 
complex (Nakatogawa et al., 2007; Weidberg et al., 2011; Kaufmann et al., 
2014). 
ATG16L1, ATG16L2 and TECPR1 all interact with ATG5 in the same 
region and thus form mutually exclusive interactions with the ATG12–ATG5 
conjugate (Kim et al., 2015).  Despite sharing a domain structure with ATG16L1, 
ATG16L2 does not catalyze LC3 conjugation and its function is unknown 
(Ishibashi et al., 2011).  TECPR1, on the other hand, has been implicated 
specifically in selective autophagy (Ogawa et al., 2011).  Binding of ATG12–
ATG5 to TECPR1 is also reported to promote its interaction with PI(3)P and the 
fusion of autophagosomes and lysosomes (Chen et al., 2012). Still, many open 
questions remain about the interplay between these different ATG5-interacting 
proteins. 
There are numerous examples of ubiquitin conjugation regulating ATG 
proteins.  Ubiquitination of Beclin 1, in particular, results in its activation or 
degradation depending on the type of polyubiquitin linkage (Reidick et al., 2014).  
Similarly, ULK1 is reportedly stabilized by Lys63-polyubiquitination while also 
being a target of proteasomal degradation (Joo et al., 2011; Nazio et al., 2013).  
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An early finding suggested that cellular levels of ATG16L1 are maintained by the 
proteasome and this was also recently found to be true for free, unconjugated 
ATG12 (Fujita et al., 2009; Haller et al., 2014).  
In this study, we have determined that DU145 PCa cells are deficient in 
autophagy due to an ATG5 donor splice-site mutation that triggers aberrant 
splicing and loss of ATG5, ATG12 and ATG16L1.  Re-expression of ATG5 in 
DU145 rescues the ubiquitination and proteasomal turnover of ATG12 and 
ATG16L1, formation of a functional ATG12–ATG5-ATG16L1 complex and 
autophagy.  We have also determined that all known alternative ATG5 protein 
isoforms are rapidly ubiquitinated and degraded and are unable to interact with 
ATG16L1, which we have found is required to stabilize ATG5 and allow 
conjugation to ATG12.  Thus, the competing conjugation reactions of ubiquitin 
and the ubiquitin-like protein, ATG12, control ATG5 stability and formation of the 
ATG12–ATG5-ATG16L1 complex.  These findings highlight the importance of 
ubiquitination and proteasomal degradation in regulating the formation of the 
ATG12–ATG5-ATG16L1 complex and autophagy. 
 
3.2 Results 
 
3.2.1 DU145 prostate cancer cells are autophagy deficient due to absence 
of the ATG12–ATG5-ATG16L1 complex.  We initially found DU145 prostate 
cancer (PCa) cells were unable to undergo LC3B lipidation, which is an essential 
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step in autophagosome formation.  Bafilomycin A1 (Baf A1) alkalinizes the 
lysosome and blocks autophagic degradation of LC3 and other substrates, 
making it useful for examining autophagic flux.  Baf A1 treatment resulted in the 
accumulation lipid-conjugated LC3B (LC3-II), an autophagosome marker, in 
LNCaP and PC-3 cells, indicating the treatment inhibited autophagic flux.  
Surprisingly, however, LC3-II remained undetectable in DU145 cells, suggesting 
that either the levels of basal autophagy were extremely low in this particular cell 
line or that a potential defect existed in the LC3 ubiquitin-like conjugation reaction 
(Fig. 3.1A).   
To address these possibilities, we starved DU145 PCa cells and A549 
lung cancer cells in nutrient-free media, which is known to induce robust 
autophagosome formation detectable by transmission electron microscopy (TEM) 
(Eskelinen, 2008).  Autophagic vacuoles were readily detected in A549 cells after 
starvation; however, we did not find evidence of autophagosome formation in 
DU145 cells (Fig. 3.1B).  To further investigate whether the lack of observed 
autophagosomes corresponded with a block in actual autophagic protein 
degradation, we examined DU145 PCa cells and A549 lung cancer cells for the 
turnover of radioactively labeled long-lived proteins in response to starvation.  
Control and starved cells were simultaneously treated with or without the PI3K 
and autophagy inhibitor, 3-methyladenine (3-MA).  3-MA blocks PI(3)P formation 
and thus, prevents autophagosome formation.  We calculated the difference in 
the amount of protein degradation between untreated and 3-MA-treated cells in 
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Figure 3.1 – DU145 PCa cells are autophagy-deficient due to absence of the 
ATG12–ATG5-ATG16L1 complex.  (A) LNCaP, PC-3 and DU145 PCa cells were treated with 
DMSO or Bafilomycin A1 (Baf A1).  Cell lysates were then prepared and immunobloted for LC3B and 
ȕDFWLQ.  LC3-I and LC3-II are the cytosolic and lipid-conjugated forms of LC3, respectively.  (B) 
Transmission electron microscopy (TEM) was used to examine autophagosome formation in DU145 
PCa cells and A549 cells after starvation.  White arrows indicate autophagic vacuoles.  (C) The 
3-methyladenine (3-MA) sensitive degradation of radioactively labeled long-lived proteins in 
response to starvation was monitored in DU145 PCa cells and A549 lung cancer cells.  DU145 cells 
did not survive beyond 12 h of complete starvation (data not shown).  (D) Cell lysates of LNCaP, 
PC-3 and DU145 PCa were immunoblotted for ATG proteins.  
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order to isolate autophagy-specific degradation and exclude other potential forms 
of protein turnover.  This approach yielded robust starvation-induced protein 
degradation in A549 cells that was completely absent in DU145 cells (Fig. 3.1C). 
Together, these data confirmed that DU145 PCa cells were autophagy-
deficient due to an apparent absence of LC3 lipid conjugation, which was 
essential for the formation of an autophagosome and for autophagic degradation.  
We then examined the levels of other ATG proteins in LNCaP, PC-3 and DU145 
cells in an attempt to identify the mechanism behind the loss of LC3 conjugation 
(Fig. 3.1D).  Strikingly, the levels of ATG5, the ATG12–ATG5 conjugate, and 
ATG16L1 were entirely absent in DU145 cells, while the levels of ULK1 and 
Beclin 1-PIK3C3 complex components were relatively comparable.  Only 
unconjugated ATG12 was detectable in DU145 cells, albeit at lower levels.  
TECPR1, which interacts with the ATG5–ATG12 conjugate at the same region as 
ATG16L1, was not lost in DU145 cells, which indicated the loss is specific to the 
ATG12–ATG5-ATG16L1 complex.  Since the ATG12–ATG5-ATG16L1 complex 
is essential for LC3 conjugation, its absence explained why LC3-II was not 
detected in response to Baf A1 treatment in DU145 cells (Fig. 3.1A).  The 
absence of the ATG12–ATG5-ATG16L1 complex was directly correlated with a 
high level of the autophagy substrate, p62, in DU145 cells compared to LNCaP 
and PC-3 cells, which further indicated a block in autophagic flux (Fig. 3.1D). 
 
	   61	  
3.2.2 ATG5, ATG12 and ATG16L1 are coordinately degraded by the 
proteasome when not associated with the ATG12–ATG5-ATG16L1 complex.  
The near total loss of ATG12 and the complete absence of ATG5 and ATG16L1 
in DU145 PCa cells suggested that either DU145 cells had a simultaneous 
genetic deficiency in both ATG5 and ATG16L1 or the individual subunits of the 
ATG12–ATG5-ATG16L1 complex were coordinately downregulated.  The 
simplest mechanism for the simultaneous loss of ATG5, ATG12 and ATG16L1 
was proteasomal degradation of the entire complex. 
To test this possibility, we treated LNCaP, PC-3 and DU145 cells with the 
reversible proteasome inhibitor, MG132.  MG132 treatment significantly 
increased unconjugated ATG12 levels in both PC-3 and DU145 cells (Fig. 3.2A, 
lanes 4 and 6), which indicated that it was being continually expressed and 
degraded by the proteasome.  Additionally, MG132 treatment partially rescued 
ATG16L1 levels in DU145 cells, but had no effect on ATG16L1 in LNCaP or PC-
3 cells (Fig. 3.2A, lanes 2, 4, and 6).  This suggested that either that proteasomal 
turnover of ATG16L1 occurs only in DU145 cells or that its degradation only 
occurs in the absence of the ATG12–ATG5 conjugate.  Finally, MG132 did not 
rescue any detectable ATG5 in DU145 cells, which meant that these cells were 
potentially ATG5-deficient (Fig. 3.2A).  If unconjugated ATG12 is continually 
degraded and ATG16L1 is degraded only in the absence of the ATG12–ATG5 
conjugate, then a specific loss of ATG5 in DU145 cells would explain the 
proteasomal-dependent elimination of the remaining subunits of the complex. 
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To test this prediction, we stably expressed ATG5 in DU145 PCa cells.  
ATG5 expression in DU145 cells rescued both ATG12 conjugation and ATG16L1 
levels.  We confirmed that ATG5 expression rescued functional ATG12–ATG5-
ATG16L1 complex formation by examining the levels of p62 (Fig. 3.2B, lanes 1 
and 3) and lipid-conjugated LC3-II (Fig. 3.2B, lanes 2 and 4), both of which 
indicated a rescue of functional autophagy.  Proteasome inhibition is known to 
robustly activate autophagy (Park and Cuervo, 2013), which explains why LC3 
lipid conjugation was readily detected upon MG132 treatment in ATG5 
expressing DU145 cells, but not in control cells (Fig. 3.2B, lanes 2 and 4). 
MG132 treatment had no effect on the ATG12–ATG5 conjugate levels, but 
it did result in the drastic accumulation of unconjugated ATG5 along with a ladder 
of higher molecular weight species generally indicative of polyubiquitination (Fig. 
3.2B, lane 4).  This suggested that unconjugated ATG5 was continually 
ubiquitinated and degraded by the proteasome similar to unconjugated ATG12.  
The more obviously apparent polyubiquitination of ATG5 was likely due to the 
rate of expression of exogenous ATG5 compared to that of endogenous ATG12.  
Together these data suggest that unconjugated ATG5 and ATG12 are continually 
degraded by the proteasome even with intact ATG12–ATG5 conjugate present, 
while ATG16L1 appears to be degraded only in the absence of the ATG12-ATG5 
conjugate.  This model can explain why, the DU145 ATG5-deficiency resulted in 
the proteasomal degradation of ATG12 and ATG16L1. 
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To determine if ubiquitination and proteasomal regulation of ATG12 and 
ATG16L1 occurs in other cell types, we used RNA interference to knockdown 
ATG5 in PC-3 PCa cells (Fig. 3.2C).  Stable knockdown of ATG5 using two 
different shRNAs resulted in a drastic reduction in the total amount of ATG12, 
both conjugated and unconjugated, as well as reduced ATG16L1 levels (Fig. 
3.2C, lanes 1, 3 and 5).  MG132 treatment partially rescued ATG16L1 and 
unconjugated ATG12 levels (Fig. 3.2C, lanes 4 and 6), which confirmed that loss 
of ATG5 triggers proteasomal degradation of ATG12 and ATG16L1 in other cell 
types.  Since MG132 treatment was limited to 8 h to avoid excessive toxicity, the 
modest effect on the accumulation of ATG16L1 was most likely due to low basal 
rate of ATG16L1 expression in these cells. 
 
3.2.3 ATG5 and ATG16L1 partially stabilize one another independently of 
ATG12, although a fully assembled ATG12–ATG5-ATG16L1 complex is 
required for maximum stability of ATG12, ATG5 and ATG16L1.  We have 
determined that loss of ATG5 resulted in the complete proteasomal degradation 
of ATG12 and ATG16L1 in multiple cell types.  In ATG5 re-expressing DU145 
cells, MG132 treatment increased levels of unconjugated ATG12 and ATG5 
while the ATG12–ATG5 conjugate remained unaffected.  This suggested the 
ATG12–ATG5 conjugate was stable and that unconjugated ATG12 and ATG5 
were inherently unstable.  Unlike ATG12 or ATG5, ATG16L1 did not undergo 
proteasomal degradation in the presence of the ATG5-ATG12 conjugate, which 
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suggested its stability is dependent on the fully assembled ATG12–ATG5-
ATG16L1 complex.  Although the current model for ATG12–ATG5-ATG16L1 
complex formation suggests that ATG12 conjugation to ATG5 occurs prior to its 
interaction with ATG16L1 (Fig. 1.5, p.29), it remained possible that ATG16L1 
stability was dependent upon ATG5 expression alone and not on formation of the 
ATG12–ATG5 conjugate. 
To distinguish between these possibilities we needed a way to uncouple 
ATG5 expression from conjugation to ATG12.  To do this, we stably expressed a 
mutant version of ATG5 that cannot undergo conjugation due to mutation of the 
target Lys-130.  This K130R mutation completely blocked ATG12 conjugation 
and formation of a functional complex as determined by p62 degradation (Fig. 
3.3A, lanes 3 and 5) and LC3 lipidation (Fig. 3.3A, lanes 4 and 6).  Despite the 
complete block in ATG12 conjugation, which was predicted to be required for 
ATG5 stability, the unconjugated ATG5 (K130R) was incompletely degraded and 
remained stably expressed, albeit at lower levels than wild-type ATG5.  The 
mutant also rescued ATG16L1 levels, but to a lesser extent than wild-type ATG5 
(Fig. 3.3C, lanes 3 and 5).  This suggested that ATG5 may partially rescue 
ATG16L1 from proteasomal degradation, independent of ATG12 conjugation. 
Since unconjugated, wild-type ATG5 is readily degraded by the 
proteasome (Fig. 3.3A lanes, 3 and 4), the partial stability of ATG5 (K130R) 
could be because Lys-130 is an important residue for ubiquitination or 
proteasome turnover.  Another possibility is that unconjugated ATG5 and 
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A. B.
C.
Figure 3.3 – ATG5 and ATG16L1 partially stabilize one another independently of ATG12, 
although the fully assembled ATG12–ATG5-ATG16L1 complex is required for maximum 
stability.  (A) DU145 cells stably expressing an empty vector, wild-type FLAG-ATG5 (WT) or 
FLAG-ATG5 (K130R) were treated with DMSO or MG132.  Lysates were prepared and 
immunoblotted for ATG proteins.  (B) DU145 cells stably expressing an empty vector, ATG5, 
ATG16L1-HA or both ATG5 and ATG16L1-HA together were treated with DMSO or MG132.  Cell 
lysates were prepared and immunoblotted for ATG proteins.  (C) Lysates prepared from Atg7, Atg12, 
and Atg5 wild type (+/+) and knockout (-/-) MEFs were immunoblotted for ATG proteins.  (D) DU145 
cells stably expressing an empty vector (EV), wild-type ATG5, C-terminally HA-tagged wild-type 
ATG16L1 or N-terminally deleted ATG16L1 (ǻ1-39) were treated with DMSO or  MG132.  Lysates 
were prepared and immunoblotted for ATG5, ATG16L1 and Į-Tubulin. ubiquitination and 
proteasomal degradation.
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ATG16L1 interact independently of ATG12 and partially stabilize one another.  
Treatment of ATG5 (K130R) expressing DU145 cells with MG132 had no 
obvious effect on ATG16L1, but still resulted in the accumulation of unconjugated 
ATG5 along with laddering typical of polyubiquitination (Fig. 3.3A, lane 6).  While 
this did not completely rule out that K130 was an important site for ubiquitination 
and turnover, it did show that K130 was clearly not the only available 
ubiquitination target on ATG5. 
The fact that MG132 treatment caused the accumulation of 
polyubiquitinated ATG5 (K130R), but had no obvious effect on ATG16L1 could 
be related to their relative expression levels.  ATG5 (K130R) was expressed at a 
much higher level than endogenous ATG16L1; which, assuming a 1:1 
stoichiometry, would result in excess unbound ATG5 that could then be 
ubiquitinated and degraded.  Therefore, while overexpression of ATG5 (K130R) 
may have driven the equilibrium towards mutual interaction and artificially 
stabilized both proteins, the excess ATG5 (K130R) not bound to ATG16L1 was 
still capable of being ubiquitinated and degraded.  Similarly, it is likely that 
unconjugated wild-type ATG5 was turned over because it was also expressed in 
excess and the endogenous ATG16L1 was likely fully saturated with the ATG5-
ATG12 conjugate (Fig. 3.3A, lane 3 and 4). 
  Co-expressing exogenous wild-type ATG5 and ATG16L1 at similar levels 
in DU145 cells resulted in the stabilization of both ATG16L1 and unconjugated 
ATG5 compared to the levels upon expression of each protein alone (Fig. 3.3B, 
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lanes 3, 5 and 7).  MG132 treatment of ATG16L1 or ATG5 expressing DU145 
cells resulted in a drastic accumulation of polyubiquitinated ATG16L1 and 
unconjugated ATG5, which confirmed these proteins are highly unstable when 
expressed in excess (Fig. 3.3B, lanes 4 and 6).  However, co-expression of 
ATG5 and ATG16L1 largely reduced, or even completely eliminated, the 
ubiquitination and proteasomal degradation of each protein (Fig. 3.3B, lane 8).  
This strongly indicates that these proteins were capable of stabilizing one 
another by preventing ubiquitination and proteasomal degradation. Co-
expression did not result in any increase in the amount of ATG12–ATG5 
conjugate, which is likely because all available ATG12 had already undergone 
conjugation with ATG5 expression alone (Fig. 3.3B, lanes 5 and 7). 
To examine the stability of ATG16L1 and unconjugated ATG5 at 
endogenous levels in a non-overexpression system, we used mouse embryonic 
fibroblasts (MEFs) containing genetic deletions of Atg5, Atg12 or Atg7, the latter 
of which encodes for an E1-like enzyme essential for Atg12 conjugation (Fig. 
3.3C).  As expected, inactivation of ATG12 conjugation, through genetic deletion 
of Atg7 or Atg12, completely blocked formation of the ATG12–ATG5 conjugate, 
although to our surprise, this did not coincide with a dramatic increase in the 
amount of unconjugated ATG5.  Instead, a low level of unconjugated ATG5 was 
detected, which corresponded with a significant decrease in ATG16L1 levels 
(Fig. 3.3C, lanes 1-4).   This indicated that, at endogenous expression levels, the 
ATG5-ATG16L1 interaction only provides slight, partial protection from 
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proteasomal turnover.  If an equilibrium exists between the stabilizing ATG5-
ATG16L1 interaction and dissociation that leads to proteasomal turnover of 
ATG5 and ATG16L1, then the removal of the unbound subunits from the 
equilibrium would shift the equilibrium more towards dissociation and turnover 
(Fig. 3.4).  This could explain why endogenous ATG5 and ATG16L1 only partially 
protected one another from proteasomal degradation. 
Since co-expression of ATG5 and ATG16L1 resulted in reciprocal 
protection from ubiquitination and turnover, we suspected the binding sites 
through which these proteins interacted were shared by the unknown E3 ligases 
that mediated their ubiquitination, thereby shielding them.  Indeed, ATG16L1 
binds to ATG5 solely through its N-terminus (Otomo et al., 2013); therefore, this 
region may also recruit E3 ligases responsible for ATG16L1 ubiquitination and 
turnover.  To test this hypothesis, we stably expressed wild-type ATG16L1 and a 
N-terminal deleted version of ATG16L1 (Δ1-39) in DU145 cells (Fig. 3.3D).  
Interestingly, this N-terminal deletion almost entirely blocked its ubiquitination 
and turnover.  This suggested that individual ATG5-ATG16L1 binding surfaces 
also recruit unknown E3 ligases that mediate their ubiquitination and turnover 
(Fig 3.3D). 
In summary, these data indicate that: (1) the DU145 autophagic defect is 
due to the specific absence of ATG5 expression and the subsequent 
proteasomal degradation of ATG12 and ATG16L1; (2) the ATG12–ATG5 
conjugate is stable, while both unconjugated ATG5 and ATG12 are inherently 
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Figure 3.4 – Proposed model for ATG12–ATG5-ATG16L1 complex assembly.  ATG16L1 and 
unconjugated ATG12 and ATG5 are rapidly ubiqiuitinated by unknown E3 ligases, which promotes 
their proteasomal degradation.  ATG5 and ATG16L1 form a mutually protective interaction by 
shielding E3 ligase recruitment sites.  This stabilizes the ATG5-ATG16L1 intermediate and allows 
ATG12 conjugation to ATG5 to occur, thus stabilizing ATG12 and the ATG5-ATG16L1 interaction.  
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unstable and are continually ubiquitinated and degraded by the proteasome; and 
(3) ATG5 and ATG16L1 can, at least partially, protect one another from 
ubiquitination and proteasomal turnover, independent of ATG12 conjugation. 
Therefore, we propose a model in which the reversible interaction 
between ATG16L1 and ATG5 prevents recruitment of E3 ligases that mediates 
ubiquitination and degradation of each protein.  This stabilizes the intermediate 
and allows ATG12 conjugation to occur and form a stable ATG12–ATG5-
ATG16L1 complex (Fig. 3.4).  This model is a significant deviation from the 
current model suggesting ATG12–ATG5 conjugation occurs prior to its 
association with ATG16L1 (Fig. 1.5, p.29).  Based on this proposed model, one 
would predict that ATG16L1, or another protein capable of stabilizing ATG5, is 
essential for ATG12 conjugation to ATG5.  In the next few sections of this 
chapter, we will prove that is indeed the case. 
 
3.2.4 A splice donor-site mutation within intron 6 causes aberrant ATG5 
mRNA splicing and skipping of exon 6 in DU145 PCa cells.  Having shown 
that DU145 PCa cells do not express ATG5, which results in the proteasomal 
degradation of ATG12 and ATG16L1 as well as the coordinated downregulation 
of FIP200 and ATG13, we set out to identify the mechanism for the loss of ATG5 
expression.  Given the possibilities that DU145 cells were genetically deficient in 
ATG5 or simply transcriptionally repressed ATG5 expression, we decided to 
examine ATG5 mRNA expression levels.  We isolated mRNA from DU145 PCa 
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cells and performed RT-PCR to amplify ATG5 transcripts (Fig. 3.5A).  
Surprisingly, the ATG5 mRNA was readily detected; however, we did note more 
than one band that was suggestive of ATG5 alternative mRNA splicing.  All 
visible bands were isolated, cloned and sequenced, revealing that two novel, 
alternative splice variants were expressed in DU145 cells, while full length ATG5 
was absent.  One variant contained an exon 6 deletion and the other was 
missing exons 3 and 6.  We presumed these splice variants were not translated 
into functional ATG5 proteins and thus, DU145 PCa cells were ATG5-deficient 
due to alternative mRNA splicing of ATG5. 
Unfortunately, during our more in-depth investigation into this finding, this 
novel alternative splicing and loss of ATG5 expression was discovered and 
published by another group (Ouyang et al., 2013).  However, why DU145 PCa 
cells were ATG5-deficient was not investigated.  Therefore, many interesting 
mechanistic questions remained unanswered.  Since both novel splice variants 
identified in DU145 cells contained deletions of exon 6, we suspected there might 
be a genetic alteration in this region that might be disrupting normal ATG5 
splicing.  Using DU145 genomic DNA as template, we PCR amplified the region 
surrounding exon 6, cloned and sequenced several of the resulting clones.  As 
predicted, we identified a mutation (c.573+1G>A) at the most 5´ nucleotide of 
intron 6, which is the location of the highly conserved GT splice donor consensus 
sequence (Fig 3.5B).  Mutation of the splice donor site of intron 6 is predicted to 
prevent nucleophilic attack by the 2´ hydroxyl group of the conserved branch-site 
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Figure 3.5 – A splice donor-site mutation within intron 6 of ATG5 causes aberrant mRNA 
splicing and skipping of exon 6 in DU145 PCa cells.  (A) RT-PCR for ATG5 using mRNA isolated 
from DU145 PCa cells.  The identified splice variants are indicated.  (B) Sequencing chromatogram 
of the PCR amplified exon 6–intron 6 boundary of DU145 PCa cells.  The DU145 genomic sequence 
is compared to the NCBI RefSeq consensus sequence.  (C) Diagram of normal ATG5 splicing and 
the proposed mechanism of exon 6 skipping caused by the DU145 donor splice-site mutation.
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adenosine residue within intron 6 (Patel and Steitz, 2003).  Instead, attack should 
occur at the next upstream splice donor site located at the 5´ end of intron 5, 
resulting in the “skipping” of exon 6 by aberrant removal of exon 6 along with 
introns 5 and 6 (Fig. 3.5C). 
After identifying the splice-site mutation, we consulted the COSMIC Cell 
Line Project database (cancer.sanger.ac.uk) to verify if genome sequencing had 
identified this same mutation in DU145 cells (Forbes et al., 2011).  The 
c.573+1G>A mutation was listed in the database and was classified as 
homozygous and unverified in DU145 cells.  Therefore, we propose that this 
mutation is the sole cause of ATG5 alternative splicing and the autophagy 
deficiency in DU145 prostate cancer cells and is not an artifact of PCR or 
sequencing. 
 
3.2.5 All alternative ATG5 protein isoforms are non-functional due to rapid 
ubiquitination and proteasomal degradation.  ATG5 spans approximately 141 
kb on the minus strand of chromosome 6 and comprises a total of 8 exons (Fig. 
3.6A).  Including our recently identified DU145 ATG5 splice variants, seven 
potentially coding ATG5 splice variants have been identified to date, according to 
Aceview and National Center for Biotechnology Information (NCBI) RefSeq 
databases (Thierry-Mieg and Thierry-Mieg, 2006; Pruitt et al., 2014) (Fig. 3.6A).  
All alternative ATG5 splice variants, with the exception of variant 2 (v2), contain 
alternative translational start sites and/or premature stop codons and, thus, are 
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potential targets of nonsense-mediated mRNA decay (NMD) that may preclude 
expression of the encoded alternative ATG5 protein isoforms.  Splice variants 6 
and 7 (v6 and v7), which we identified in DU145 cells, are designated as targets 
for NMD by the NCBI RefSeq database, although this has not been empirically 
verified. 
We did not detect any alternative ATG5 protein isoforms in LNCaP, PC-3 
or DU145 cells even after 8 h of MG132 treatment (Fig. 3.2C).  This could be 
indicative of NMD targeting of the ATG5 splice variants; however, the fact that 
full-length ATG5, which is readily expressed in LNCaP and PC-3 cells, also did 
not accumulate after MG132 treatment suggests endogenous ATG5 expression 
rates are simply not high enough to detect the rapidly degraded unconjugated 
forms of ATG5 within the allowable 8 h of proteasome inhibition.  All ATG5 splice 
variants, including full-length ATG5, contain an upstream open reading frame 
(uORF) in 5´ untranslated region (UTR) of exon 2, which precedes the 
translational start site (Fig. 3.6A). uORFs have been correlated with translational 
repression of downstream ORFs (Barbosa et al., 2013), meaning they could be 
responsible for the low rate of ATG5 expression.  However, the specific effects of 
uORFs and NMD are not well understood, and it is difficult to predict exactly how 
they might regulate expression of full-length ATG5 or its alternative protein 
isoforms. 
In order to overcome the inability to detect endogenous, unconjugated 
ATG5 protein isoforms, we exogenously expressed HA-tagged versions in 
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Figure 3.6 – All known alternative ATG5 protein isoforms are non-functional due to rapid 
ubiquitination and proteasomal degradation.  (A) Diagram of all known ATG5 alternative splice 
variants.  (B) Table listing mRNA accession numbers of all known ATG5 splice variants and the 
predicted amino acid alterations of their encoded isoforms.  (C) Diagram of ATG5 domain structure 
and predicted ATG5 protein isoforms.  Full-length ATG5 consists of an N-terminal Į-helix (ĮWZR
XELTXLWLQOLNHIROGGRPDLQV8)'DQG8)'DQGDKHOL[EXQGOHUHJLRQ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DU145 cells to determine if any of the predicted alternative ATG5 protein 
isoforms were capable of conjugating to ATG12 and forming a functional ATG12-
–ATG5-ATG16L1 complex.  The predicted amino acid alteration for each splice 
variant is listed in Fig. 3.6B and diagrammed in Fig. 3.6C.  Full-length ATG5 
contains an N-terminal α-helix domain (α1), followed by two ubiquitin-fold 
domains (UFD-1 and UFD-2) that flank a helix bundle region (HBR) containing 
Lys-130, which is the site of ATG12 conjugation (Fig. 3.6C).  Splice variant 2 
contains an alternative exon 1, which affects only the 5´ UTR and is still predicted 
to encode for full-length ATG5.  Splice variants 3 and 7, encoding isoforms b and 
f respectively, have predicted alternative translational start sites that create N-
terminal deletions.  Splice variant 7 (encoding isoform f), in addition to variants 5 
and 6 (encoding isoforms d and e, respectively) are missing one or more exons, 
creating frameshifts and introducing premature stop codons that are predicted to 
cause C-terminal truncations.  Splice variant 4 contains an alternative exon 6, 
likely resulting from cryptic splicing, which also introduces a frameshift and 
premature stop codon predicted to encode for a severely truncated ATG5 isoform 
d (Fig. 3.6B and 3.6C). 
Stable expression of all ATG5 protein isoforms clearly revealed that only 
full-length ATG5 expression rescued ATG12 and ATG16L1 turnover (Fig. 3.6D).    
Rescue of p62 degradation and LC3 lipid-conjugation was also only seen for full-
length ATG5 and not for any of the other ATG5 isoforms (Fig. 3.6D).  All the 
alternative ATG5 protein isoforms were nearly undetectable in cells not treated 
	   78	  
with MG132, suggesting they may be degraded by the proteasome.  Indeed, in 
the presence of MG132, the levels of unconjugated ATG5, including full-length 
and all alternative isoforms, were dramatically increased, along with a laddering 
of higher molecular weight bands indicative of polyubiquitination.   
In summary, while we cannot rule out the possibilities that endogenous 
ATG5 splice variants are translationally repressed by uORFs or are targeted by 
the NMD pathway, these data demonstrate that regardless of expression, all 
alternative ATG5 isoforms are inherently unstable and are unable to conjugate to 
ATG12 and form a functional complex.  Thus, alternative splicing of ATG5 is a 
highly selective mechanism capable of regulating autophagosome formation and 
autophagy.  DU145 PCa cells happen to possess a genetic mutation that 
completely disables autophagy by irreversibly inducing aberrant ATG5 splicing. 
 
3.2.6 Binding to ATG16L1 is essential for ATG5 stability and conjugation 
to ATG12.  All but one of the alternative ATG5 isoforms retained the majority of 
the helix bundle region (HBR) and the Lys-130 site of ATG12 conjugation.  
Therefore, it was not immediately apparent why these isoforms were targeted by 
ubiquitin conjugation instead of ATG12 conjugation.  All the alternative isoforms 
had deletions of the N and/or C-termini, which are more likely to affect interaction 
with ATG16L1, rather than with ATG12, based on the ATG12–ATG5-ATG16L1 
crystal structure (Otomo et al., 2013).  Since we had previously determined that 
that unconjugated ATG5 and ATG16L1 could partially protect one another from 
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proteasomal degradation (Fig. 3.3), we hypothesized that the alternative ATG5 
protein isoforms might be susceptible to ubiquitination and proteasomal 
degradation due to an inability to bind ATG16L1, which consequently prevents 
ATG12 conjugation. 
To test this prediction, we used the ATG12–ATG5-ATG16L1 crystal 
structure and a yeast Atg5-Atg16L1 peptide affinity study as guides for selecting 
ATG5 residues that might be involved in ATG16L1 binding (Otomo et al., 2013; 
Zhao et al., 2013).  We then mutated ATG5 N- and C-terminal residues located 
around the ATG16L1 binding interface by site-directed mutagenesis (Fig. 3.7A).  
Having generated multiple mutants, across all ATG5 domains, that could 
potentially disrupt its interaction with ATG16L1, we then stably expressed them in 
DU145 cells.  Interestingly, several of the mutants did not conjugate to ATG12 
and did not rescue ATG12 or ATG16L1 levels.  These mutants were only 
detectable in unconjugated and polyubiquitin-conjugated forms after MG132 
treatment, which indicated that they were ubiquitinated and degraded instead of 
conjugated to ATG12 (Fig. 3.7A). 
These results confirmed that specific disruption of the ATG5-ATG16L1 
interaction leads to the proteasomal turnover of both ATG5 and ATG16L1, 
thereby preventing its conjugation to ATG12, which is also subsequently 
degraded.  Notably, the most effective mutations to the ATG12–ATG5-ATG16L1 
complex mapped to the critical ATG16L1 binding interface at the boundary of the 
α1-helix and the two UFD domains, comprising both the N and the C-termini (Fig. 
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A.
B. C.
Figure 3.7 – ATG16L1 binding is essential for ATG5 stability and conjugation to ATG12.  (A) 
Based on the crystal structure of the ATG12–ATG5-ATG16L1 complex, N and C-terminal ATG5 
residues along the ATG16L1 binding interface were altered by site-directed mutagenesis.  The 
diagram shows the location of the mutations within the domain structure of ATG5.   DU145 PCa cells, 
stably expressing an empty vector (EV), wild-type (WT) ATG5 or mutant ATG5, were treated with 
DMSO or MG132.  Lysates were prepared and immunoblotted for ATG proteins.  Mutations that 
dramatically disrupted ATG12 conjugation are highlighted in magenta.  (B) Surface rendering of the 
ATG12–ATG5 in complex with an N-terminal fragment of ATG16L1.  ATG5 domain colors 
correspond to the illustration in (A).  ATG16L1 N-terminal fragment (grey) is rendered as a ribbon to 
allow visualization of the critical residues at the ATG5-ATG16L1 binding interface (magenta).  ATG12 
is conjugated on the other side of ATG5, opposite the ATG16L1 interface, and is therefore not visible.  
(C) ATG16L1+/+ and ATG16L1-/- HCT116 colorectal cancer cells lines were treated with DMSO or 
MG132.  Lysates were prepared and immunoblotted for autophagy-related proteins.
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3.7B).  This explains why the ATG5 alternative isoforms, containing either N or 
C-terminal deletions, fail to conjugate to ATG12, as they are unable to form the 
requisite interaction with ATG16L1 and instead rapidly undergo ubiquitination 
and proteasomal degradation. 
To confirm ATG12 conjugation was ATG16L1-dependent, we obtained 
ATG16L1-deficient HCT116 colorectal cancer cells and tested them for ATG12 
conjugation.  ATG12–ATG5 conjugate levels were reduced compared to wild-
type cells, indicating that the ATG12 conjugation reaction is impaired in the 
absence of ATG16L1 (Fig. 3.7C).  However, ATG12 conjugation in the ATG16L1-
deficient cells was not completely abolished and still resulted in detectable levels 
of ATG12–ATG5 conjugate.  Despite the presence of detectable ATG12–ATG5 
conjugate, LC3-lipid conjugation was still inactive in ATG16L1-/- (Fig. 3.7C, lanes 
2 and 4).  This finding suggested that ATG16L1 is essential for the catalyzing 
LC3 conjugation to PE, but is not absolutely essential for ATG12 conjugation to 
ATG5. 
ATG5 can interact with ATG16L2 and TECPR1, both of which bind ATG5 
in the same region as ATG16L1 and form distinct complexes with ATG12–ATG5 
(Kim et al., 2015).  Despite the interactions with ATG12–ATG5, neither protein is 
involved catalyzing the LC3 lipid conjugation (Ishibashi et al., 2011; Ogawa et al., 
2011; Chen et al., 2012).  Therefore, at least in this cell type, it suggests 
ATG16L1 is the dominant factor in stabilizing ATG5 and mediating ATG12 
conjugation, although there is likely some level of compensation by ATG16L2 
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and/or TECPR1.  The ATG5 mutations likely disrupt interaction with all three 
proteins and, thus, have a more profound effect on ATG12 conjugation than 
simply knocking out ATG16L1 alone. 
 
3.2.7 ULK1 complex components are coordinately regulated with the 
ATG12–ATG5-ATG16L1 complex in different cell types. We have 
characterized, in depth, how subunits in the ATG12–ATG5-ATG16L1 complex 
are dependent upon one another for stability.  Interestingly, recent findings in 
MEFs indicate that FIP200 interacts directly with ATG16L1 and that the levels of 
ULK1 complex components are also reduced in Atg5-/- and Atg16Δ/Δ cells 
(Nishimura et al., 2013).  This suggests that assembly of the ATG12–ATG5-
ATG16L1 complex might also affect other protein complexes including the ULK1 
complex. 
We therefore examined the expression levels of both the ATG12–ATG5-
ATG16L1 complex as well as the ULK1 complex in previously untested wild-type 
and knockout Atg7 and Atg3 MEFs.  ATG3 is the E2-like enzyme responsible for 
LC3 conjugation.  We compared those MEFs to the previously reported Atg5+/+, 
Atg5-/- Atg16L1+/+ and Atg16Δ/Δ MEFs (Nishimura et al., 2013) (Fig. 3.8A).  As 
reported by Nishimura et al., we confirmed that ULK1, ATG13 and FIP200 levels 
are all reduced in Atg5-/- and Atg16Δ/Δ MEFs compared to their corresponding 
wild-type controls.  We also determined that Atg7-/- MEFs also had reduced ULK1 
complex levels, suggesting that ULK1 complex formation or stability is dependent 
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upon the fully assembled ATG12–ATG5-ATG16L1 complex.  The reduced levels 
of ULK1 complex subunits directly correlates with the loss of ATG16L1, which 
given its known interaction with FIP200, might mean it functions to stabilize the 
ULK1 complex. 
Surprisingly, Atg3-/- MEFs also had reduced levels of both the ATG12–
ATG5-ATG16L1 complex and the ULK1 complex when compared to wild-type 
Atg3+/+ MEFs (Fig. 3.8A, lanes 3 and 4).  While ATG12 conjugation did occur in 
these cells, the levels of the ATG12–ATG5 conjugate were reduced and this 
corresponded to a significant reduction in the level of ATG16L1.  This was a very 
unexpected result as ATG3 is thought to act downstream of the ULK1 complex 
and ATG12 conjugation.  ATG3 is known to interact with ATG12 (Noda et al., 
2013; Otomo et al., 2013; Sakoh-Nakatogawa et al., 2013); however, there is no 
obvious explanation for why the loss of an E2-like enzyme would affect the 
stability of two distinct upstream protein complexes (Fig. 1.5, p.29). 
 To confirm the coordinated regulation between the ATG12–ATG5-
ATG16L1 and ULK1 complexes, we examined the levels of ULK1 complex 
components in Atg5-/- MEFs in which murine ATG5 (mATG5) was stably re-
expressed.  As expected, ATG5 rescued formation of the functional ATG12–
ATG5-ATG16L1 complex, as determined by the levels of ATG16L1, the ATG12-
ATG5 conjugate, LC3-II and p62 (Fig. 3.8B).  Similar to earlier findings, TECPR1 
levels remained unaffected by ATG5 expression; however, mATG5 expression 
did increase the levels of ULK1, ATG13 and FIP200 (Fig. 3.8B).  To test if 
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Figure 3.8 – ULK1 complex components are coordinately regulated with the 
ATG12–ATG5-ATG16L1 complex in different cell types.  (A) Lysates were prepared from Atg7, 
Atg3, or Atg5 wild type (+/+) and knockout (-/-) MEFs, in addition to Atg16L1+/+ and Atg16L1ǻ/ǻ MEFs, 
which lack the coiled-coil domain.  Lysates were prepared and immunoblotted for ATG proteins.  (B) 
Atg5+/+ wild type and Atg5-/- MEFs, stably expressing an empty vector (EV) or FLAG-tagged murine 
ATG5 (FLAG-mATG5),  were treated with DMSO or MG132.  Lysates were prepared and analyzed 
by immunoblotting for ATG proteins.  (C) DU145 PCa cells, stably expressing an empty vector (EV), 
wild-type ATG5 or ATG5 (K130R), were treated with DMSO or MG132.  Cell lysates were then 
prepared and immunoblotted for ATG proteins.
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expression of ATG5 protected the ULK1 complex subunits from proteasomal 
degradation, we treated the cells with MG132.  Unexpectedly, this did not result 
in obvious accumulation of any of the ULK1 complex components.  Nishimura et 
al. reported that mRNA levels of ULK1 complex components are unaffected by 
ATG5 expression, indicating ULK1 complex downregulation is unlikely to be 
caused by transcriptional suppression (Nishimura et al., 2013).   Therefore it’s 
possible that either the expression rate for these proteins is too low to affect 
accumulation within 8 h of proteasome inhibition or there is a proteasome-
independent mechanism for ULK1 complex regulation. 
 Having observed a dramatic loss in ULK1 complex subunits in the 
absence of the ATG12–ATG5-ATG16L1 complex in MEFs, we wondered if the 
effect was cell-type specific since previously we did not observe drastically 
different levels of ULK1 complex subunits in DU145 cells when compared to 
other PCa cells (Fig. 3.1D).  To verify that the coordinated regulation between the 
ULK1 and ATG12–ATG5-ATG16L1 complexes occurs in other cell types, we 
examined DU145 PCa cells stably expressing ATG5 (Fig. 3.8C).  ATG5 
expression increased the levels of ATG13 and FIP200, although it did not 
significantly affect ULK1 levels.  Therefore, there is clearly a significant level of 
crosstalk between these two complexes; however, there are also cell type 
differences with regards to the stability of ATG12-ATG5-ATG16L1 and ULK1 
complex components in MEFs and DU145 cells.  The ULK1 complex is thought 
to be involved in recruitment of the ATG12–ATG5-ATG16L1 complex to the 
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isolation membrane (Nishimura et al., 2013), although its unclear how this might 
relate to the stabilities of each complex. 
 
3.3 Discussion 
 
 Our initial observation that DU145 PCa cells did not undergo LC3 
lipidation led to our discovery that a splice donor-site mutation results in aberrant 
splicing of ATG5 and the inactivation of autophagy.  To our knowledge, this is the 
first mutation identified in a cancer cell line or tumor sample that has been proven 
to completely inactivate autophagy.  Having made this discovery, an obvious 
question is whether ATG5 genetic mutations occur in primary human tumor 
samples and inactivate autophagy through similar mechanisms.  This question 
will be addressed in the next chapter. 
We also determined that the DU145 splice donor-site mutation irreversibly 
activated a highly specific mechanism for toggling autophagy on and off through 
alternative splicing of ATG5.  ATG5 is an immensely important gene for 
regulating autophagy and there are no other genes that functionally compensate 
for it (Feng et al., 2014).  Its inactivation also leads to the coordinated 
downregulation of numerous other autophagy-related proteins including ATG12, 
ATG16L1 and ULK1 complex proteins.  Since autophagy appears to function 
both as a tumor suppressor and a tumor promoter depending on the stage and 
context (Galluzzi et al., 2015), ATG5 splicing may serve as an important, 
	   87	  
reversible modulator of autophagy during tumorigenesis and progression.  It is 
imperative that we further investigate how ATG5 splicing is regulated and 
determine if tumor cells are capable of switching autophagy on and off at 
different stages of tumorigenesis via ATG5 splicing.  If certain kinases control 
ATG5 splicing, they would make intriguing therapeutic targets that could 
selectively activate or inactivate autophagy to enhance the efficacy of 
chemotherapy.  In a similar vein, we have successfully characterized the binding 
region most critical for ATG5-ATG16L1 interaction, in vivo, which could be used 
to develop small molecule or peptides inhibitors that disrupt this interaction and 
inhibit autophagy with high selectivity, which currently available inhibitors do not 
provide. 
Our findings in DU145 cells reveal that they are an excellent tool for 
investigating the, as yet, undefined mechanisms that regulate ATG12–ATG5-
ATG16L1 complex formation.  Proteasomal degradation of ATG16L1 and ATG12 
has been previously reported (Fujita et al., 2009; Haller et al., 2014), but not, to 
our knowledge, for ATG5.  Additionally, we are the first group to clearly describe 
the coordinated and rapid ubiquitination and proteasomal degradation of ATG12–
ATG5-ATG16L1 complex subunits, as well as the importance of the ATG5-
ATG16L1 interaction for facilitating ATG12 conjugation. 
These novel findings introduce many new intriguing questions regarding 
the assembly and regulation of the ATG12-ATG5-ATG16L1 complex.  Given that 
rapid ubiquitination and degradation essentially eliminates all free, unbound 
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forms of ATG5, ATG12 and ATG16L1 and that ATG16L2 and TECPR1 also 
compete for available ATG5, it is rather incredible that functional ATG12–ATG5-
ATG16L1 complexes are formed in the cell at all.  There may well be unidentified 
factors that prevent proteasomal degradation and mediate assembly of the 
complex. Regardless, once formed, the complex appears to be very stable, 
suggesting that its formation and/or disassembly is unlikely to occur in rapid 
response to an autophagy stimulus.  Thus, it seems more likely that a pool of 
ATG12–ATG5-ATG16L1 complex is maintained in the cell where its activity, 
rather than its formation, is specifically modulated in response to an autophagy 
stimulus, perhaps through interaction with WIPI2 or the ULK1 complex. 
The extensive degradation of free, unbound ATG5, ATG12 and ATG16L1 
may indicate that having substantial levels of these subunits may be deleterious 
to the cell.  ATG12 has been reported to function in mitochondrial homeostasis 
and apoptosis, independently of ATG5 (Radoshevich et al., 2010; Haller et al., 
2014).  Thus, other non-autophagic functions for free ATG12, ATG5 or ATG16L1 
may be normally repressed by rapid proteasomal turnover.  The same might be 
true for ULK1 complex subunits, given that it is also downregulated in response 
to loss of the ATG12–ATG5-ATG16L1 complex.  FIP200, also known as 
RB1CC1, interacts with a variety of non-autophagy-related proteins and functions 
as a signaling node for many different signaling pathways (Gan and Guan, 2008).  
Thus, our ability to regulate formation of the ATG12–ATG5-ATG16L1 complex 
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should allow us to isolate unique and novel functions of ATG12-ATG5-ATG16L1 
and ULK1 complex subunits. 
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Chapter 4: Downregulation of ATG5 in Prostate Cancer 
 
4.1 Introduction 
 
 Advances in next-generation sequencing (NGS) have revolutionized the 
fields of clinical diagnostics and cancer biology by revealing recurrent genetic 
alterations that can be used to guide personalized treatment of cancer patients.  
While, historically, cancers were thought to be driven by the accumulation of 
single mutations over time, it is increasingly clear that large-scale chromosomal 
alterations are not only frequent, but are important drivers of tumor progression, 
particularly for prostate cancer (PCa) (Williams et al., 2014).  The discovery of 
the transmembrane protease, serine 2 – E twenty-six transcription factor family  
(TMPRSS2–ETS) gene fusions in PCa, which occur in roughly 50% of advanced 
prostate tumors, made it the first solid cancer found to have recurring large-scale 
chromosomal rearrangements (Tomlins et al., 2005).  Recently, complex 
chromosomal rearrangement events, known as chromoplexy, were shown to 
frequently occur in PCa and are thought to drive genetic alterations, prostate 
tumor evolution and progression.  This process involves coordinated structural 
rearrangements across multiple chromosomes, which can create oncogenic gene 
fusions and disrupt numerous tumor suppressor genes in one single 
rearrangement event (Baca et al., 2013).   
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Copy number analysis, using comparative genomic hybridization (CGH), 
has identified frequently occurring chromosomal alterations in tumors affecting 
loci containing genes traditionally implicated in PCa, such as 8q [v-myc avian 
myelocytomatosis viral oncogene homolog (MYC)], 10q [phosphatase and tensin 
homolog (PTEN)], 12p [cyclin-dependent kinase inhibitor 1B (CDKN1B/p27)], 13q 
[retinoblastoma 1 (RB1)] and 17q (TP53), in addition to several other regions with 
no well-established driver gene (Taylor et al., 2010).  Still, the clinical relevance 
of many of these structural alterations is unknown.  The total copy number 
alteration burden was recently shown to predict the likelihood of biochemical 
relapse of intermediate-risk Gleason 7 grade tumors (Hieronymus et al., 2014).  
Distinguishing indolent from highly aggressive clones within this intermediate risk 
tumor population is critical for mitigating overtreatment of prostate cancers that 
would normally pose little risk to patient quality of life for many years.  
Interestingly, deletions of chromosomal locus 6q21, which contains ATG5, 
occurs in 47% of total PCa samples and 74% of advanced PCa cancers, making 
it one of the most frequently altered regions in PCa (Williams et al., 2014).  
Additionally, a subtype of PCa defined by mutations in speckle-type POZ protein 
(SPOP), was found to be almost exclusively enriched for deletions of 6q21 loci 
(Barbieri et al., 2012).  Despite this, ATG5 has been completely overlooked as a 
putative prostate tumor suppressor gene and the role of autophagy in PCa is 
unknown. 
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The earliest genetic evidence implicating autophagy in tumorigenesis 
came from a pair of studies that concluded Beclin 1 was a haploinsufficient tumor 
suppressor based on the finding that Becn1+/- mice spontaneously developed 
lymphomas, lung and liver cancers with high frequency (Qu et al., 2003; Yue et 
al., 2003).  However, Beclin 1 has since been shown to prevent the ubiquitination 
and proteasomal degradation of the tumor suppressor, p53, while also promoting 
proteasomal degradation of the anti-apoptotic Bcl-2 family member, Mcl-1 (Liu et 
al., 2011; Elgendy et al., 2014).  Loss of either of these functions could contribute 
to tumorigenesis in Becn1+/- mice, raising doubts as to whether the Beclin 1 
tumor suppressive function is actually dependent upon its role in autophagy. 
 Other autophagy-specific mouse models, including the mosaic deletion of 
Atg5 or liver-specific deletion of Atg7, also result in the spontaneous 
development of liver tumors, although the tumors remain benign and do not 
progress to malignancy (Takamura et al., 2011).  This was the first indication that 
autophagy may play opposing roles in tumor initiation and progression.  
Knockout of Atg5 or Atg7 in established mouse models of cancer, including 
BRAFV600E and KRASG12D-driven lung cancer models, increased tumor initiation 
while also increasing overall mouse survival by suppressing tumor progression 
(Strohecker et al., 2013; Rao et al., 2014).  Similar results were observed in 
KRASG12D-driven pancreatic cancer models (Rosenfeldt et al., 2013; Yang et al., 
2014).  The current hypothesis, based on these data, is that autophagy 
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suppresses tumor initiation, while also playing an essential role in tumor 
progression after a tumor is established.   
 The seemingly opposing roles of autophagy in tumorigenesis and 
progression are thought to be due to the different functions of homeostatic and 
stress-induced autophagy.  Autophagy is known to maintain homeostasis by 
eliminating damaged mitochondria and other deleterious elements that generate 
ROS and can damage DNA or promote inflammation.  Thus, autophagy 
suppresses conditions known to promote cellular transformation and tumor 
initiation (Sabharwal and Schumacker, 2014).  On the other hand, autophagy can 
be induced in tumor cells as a survival response to stressors found in the tumor 
microenvironment, during invasion and metastasis or even during tumor therapy 
(Galluzzi et al., 2015).  This potential aspect has made autophagy a therapeutic 
target of great interest.   
However, the role of autophagy in tumor progression appears to be highly 
context-specific.  In the mouse KRASG12D-driven pancreatic cancer model, the 
tumor suppressive effect of Atg5 or Atg7 deletion was completely reversed and 
actually promoted tumor progression when Trp53 was also deleted (Rosenfeldt 
et al., 2013).  Additionally, this current model is not extensively supported by 
human cancer data.  BECN1 is reportedly monoallelically deleted in numerous 
malignancies, including breast and ovarian cancer; however, recent analysis 
shows this is likely due to its proximity to the well-established tumor suppressor 
gene, breast cancer 1, early onset (BRCA1), at chromosome locus 17q21 
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(Laddha et al., 2014).  Another study indicates that ATG5 is downregulated in 
human melanoma samples, which was shown to prevent oncogene-induced 
senescence in cultured melanocytes (Liu et al., 2013a).  Thus, while numerous 
mouse models have implicated autophagy as a suppressor of tumor initiation and 
a promoter of tumor progression, this may only be true in specific tissues or in 
specific genetic backgrounds.  
 In this study, we have characterized the effects of somatic ATG5 
mutations identified in many human cancer cell types and the mechanisms for 
how they inactivate ATG5 gene function.  We have also determined that the 
frequent genetic deletions of 6q21 found in prostate tumors coincide with a 
specific decrease in ATG5 mRNA expression that does not occur for neighboring 
genes.  In fact, we have discovered ATG5 is more significantly downregulated 
than many well-established PCa tumor suppressor genes, such as PTEN and 
RB1.  Additionally, ATG5 mRNA is further downregulated in PCa metastases 
compared to primary tumors, which implicates ATG5 as a tumor suppressor even 
at later, more advanced stages of PCa. We confirmed a tumor suppressive 
function for ATG5 in a PCa xenograft model in which rescue of ATG5 in ATG5-
deficient DU145 PCa cells significantly reduced the rate of tumor growth.  
Together, these data indicate that ATG5 is inactivated in human tumors and 
strongly suggests it is a tumor suppressor at both early and late stages of 
prostate tumorigenesis.   
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4.2 Results 
 
4.2.1 Human tumor samples contain ATG5 splice region mutations that 
may cause exon skipping and result in the proteasomal degradation of 
ATG5, ATG12 and ATG16L1.  Having identified the splice donor site mutation 
(c.573+1G>A) that inactivates autophagy in DU145 PCa cells, we used publically 
available catalogs of genetic information collected from human tumor samples to 
determine if similar ATG5 splice-site mutations have been identified in other 
tumors.  We compiled a list of all somatic ATG5 splice-region and 
nonsynonymous coding sequence mutations from: the Catalogue of Somatic 
Mutations in Cancer (COSMIC: http://cancer.sanger.ac.uk/cosmic), the 
cBioPortal for Cancer Genomics (http://www.cbioportal.org) and the International 
Cancer Genome Consortium (ICGC: https://icgc.org) (Table 4.1).  These 
databases compile sequencing information originally from the Cancer Genome 
Atlas (TCGA: https://tcga-data.nci.nih.gov/tcga/), ICGC and other publically 
available tumor sequencing datasets.  As of this writing, five ATG5 splice-region 
mutations have been identified, in addition to the c.573+1G>A mutation in intron 
6 that we identified in DU145 PCa cells. 
One of the splice region mutations (c.236+1G>C), found in a hepatic 
tumor sample (Kan et al., 2013), occurs in the consensus splice donor site at the 
5´ end of intron 3 (Table 4.1).  This mutation is analogous to the c.573+1G>C 
mutation within intron 6 that results in skipping of exon 6 and the inactivation of 
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Table 4.1 – Somatic ATG5 splice region and nonsynonymous coding sequence mutations 
identified in human tumor samples. 
Mutation 
Type
Mutation (CDS) Predicted Amino Acid 
Alteration
Tumor type Sequencing Source Tumor Sample 
Count
Functional 
Classification
Splice Region
c.109-3C>G p.? Hepatic ICGC - Japan 1 *
c.236+1G>C p.M1_W79del Hepatic Kan et al., Genome Research, 2013 1 Amorph*
c.237-3delT p.? Colorectal TCGA 1 *
c.573+1G>A p.R161Nfs*2 Prostate metastasis (DU145 cell line) Current publication 1 Amorph
c.573+8A>G p.? Hepatic ICGC - Japan 1 *
c.691+9A>G p.? Hepatic ICGC - Japan 1 *
Nonsense
c.25C>T p.R9*; p.M1_V59del Brain TCGA 2 Amorph
c.43C>T p.R15*; p.M1_V59del Prostate & Brain TCGA 2 Amorph
c.157A>T p.K53* Hepatic TCGA 1 Amporh*
c.169C>T p.Q57* Squamous cell carcinoma Pickering et al., Clin Cancer Res, 2014 1 Amorph*
c.430G>T p.E144* Colorectal TCGA 1 Amorph
c.535G>T p.E179* Colorectal Seshagiri et al., Nature, 2012 1 Amorph
Deletion
c.28_31delGATG p.M1_V11del Hepatic ICGC - Japan 1 Amorph
c.36_38delGTT p.W12_F13delinsC Hepatic ICGC - Japan 1 Amorph
c.704delA p.K235Rfs*4 Gastric & colorectal TCGA & Kang et al., J. Pathology, 2009 4 Amorph
Missense
c.16G>T p.D6Y Colorectal TCGA 1
c.172A>G p.K58E Colorectal TCGA 1
c.173A>G p.K58R Colorectal TCGA 5
c.173A>T p.K58M Colorectal Sjöblom et al., Science, 2006 1
c.197G>A p.S66N Uterine TCGA 1
c.245C>T p.P82L Melenoma TCGA 1 Hypomorph
c.272C>T p.A91V Hepatic ICGC - Japan 1 *
c.286C>G p.L96V Breast TCGA 1
c.315G>T p.K105N Uterine TCGA 1
c.317G>T p.S106I Uterine TCGA 1
c.334C>T p.L112F Hepatic An et al., Pathol Res Pract, 2011 1
c.346_347CC>TT p.P116L Squamous cell carcinoma Pickering et al., Clin Cancer Res, 2014 1 *
c.397G>A p.D133N Cervical TCGA 1 *
c.449A>G p.H150R Colorectal (HCT15 cell line) Mouradov et al., Cancer Res, 2014 1 *
c.462G>T p.W154C Thyroid ICGC - Saudi Arabia 1
c.463A>G p.M155V Brain TCGA 1
c.547C>T p.R183C Melanoma TCGA 1
c.556C>T p.P186S Melanoma TCGA 1 Hypomorph
c.577A>T p.T193S Breast TCGA 1
c.580A>T p.T194S Breast TCGA 1
c.611G>A p.R204H Gastric & colorectal (SW48 cell line) Wang et al., Nature Genetics, 2014; 
Mouradov et al., Cancer Res, 2014
2 *
c.622G>A p.A208T Uterine TCGA 1
c.674C>T p.S225F Bladder TCGA 1
c.688G>A p.E230K Colorectal TCGA 1
c.705G>T p.K235N Colorectal (HCC_2998 cell line) NCI-60 1
c.721C>T p.H241Y Gastric An et al., Pathol Res Pract, 2011 1 Amorph
c.724G>A p.G242R Pancreatic ICGC - Australia 1 Amorph
c.770A>G p.H257R Hepatic TCGA 1 *
c.775A>C p.S259R Hepatic TCGA 1 *
c.782C>T p.P261L Gastric TCGA 1 Hypomorph
c.793C>A p.L265I Colorectal TCGA 1 Hypomorph
not tested*
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ATG5 in DU145 PCa cells.  Although we have not directly tested the effects of 
the c.236+1G>C mutation, given its location at the splice donor site of intron 3, it 
may result in a similar skipping of exon 3.  While this could result in NMD or 
another form of translational repression, we have already confirmed that the N-
terminally deleted form of ATG5 predicted to result from the removal of exon 3 
does not interact with ATG16L1 and is rapidly ubiquitinated and degraded (Fig. 
3.6, p.76).  Since any alteration of splicing would disrupt either the N or C-
terminus of ATG5 and would cause the complete proteasomal degradation of 
ATG5, ATG12 and ATG16L1, we therefore predict that this mutation is likely a 
null or amorphic mutation. 
Another ATG5 splice region mutation was identified in a colorectal tumor 
sample sequenced by TCGA, while the remaining splice-region mutations were 
identified in hepatic tumors sequenced by the ICGC in Japan (Table 4.1).  
However, unlike c.236+1G>C or c.573+1>C mutations, these mutations do not 
occur directly in the nearly invariable consensus splice donor or acceptor sites, 
which are limited to the two nucleotides at the 5´ and 3´ ends of each intron, 
respectively (Patel and Steitz, 2003).  However, two of them (c.109-3C>G and 
c.237-3delT) do occur at conserved splice acceptor regions, which can cover as 
many as 25 nucleotides at the 3´ end of introns (Caminsky et al., 2014).  Without 
direct experimental evidence, it is difficult to conclusively determine whether 
these splice-region mutations affect ATG5 splicing.  If they do disrupt splicing, 
this would cause either N or C-terminal deletions of ATG5, which we have shown 
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can prevent stabilization by ATG16L1 and lead to complete proteasomal turnover 
of ATG5, ATG12 and ATG16L1 (Fig. 3.6, p.76).  So while we have not directly 
tested the effects of these splice region mutations on ATG5 splicing, any 
mutation that does inactivate an ATG5 splice donor or acceptor site would 
completely disrupt ATG5 gene function and autophagy. 
 
4.2.2 All cancer-associated ATG5 nonsense and deletion mutations result 
in proteasomal degradation of ATG5, ATG12 and ATG16L1 and the 
inactivation of autophagy.  A number of ATG5 nonsense and deletion 
mutations have been identified across diverse tumor types, including prostate 
cancer. The two most 5´ nonsense mutations, c.25C>T and c.43C>T, are 
predicted to introduce small uORFs that may still allow translation initiation to 
occur at a nearby downstream methionine, which would result in an N-terminally 
deleted version of ATG5 (p.M1_V59del).  The remaining nonsense mutations are 
predicted to result in C-terminal truncations of varying lengths (Table 4.1 and Fig. 
4.1A). 
Two deletion mutations were identified in hepatic tumors by the ICGC in 
Japan.  The c.28_31delGATG mutation introduces a novel translation initiation 
site predicted to encode for an ATG5 protein containing a small N-terminal 
deletion of 10 amino acids (p.M1_V11del).  The c.26_28delGTT mutation is 
predicted to cause a small insertion/deletion in which Trp-12 and Phe-13 are 
replaced with a cysteine (p.W12_F13delinsC).  Finally, the c.704delA mutation is 
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A.
B.
Figure 4.1 – All ATG5 nonsense and deletion mutations identified in human tumor samples 
are amporphic mutations.  (A) Diagram of ATG5 nonsense and deletion mutations identified in 
human tumor samples.  p.M1_V11del and p.M1_V59del are N-terminal deletions predicted to result 
from alternative translation initiation, which cirumvents the 5´ nonsense mutations that introduce 
short uORFs.  (B) DU145 PCa cells, stably expressing an empty vector (EV), wild-type (WT) ATG5 
or various mutant ATG5s, were treated with DMSO or MG132.  Lysates were prepared and 
immunoblotted for ATG proteins.
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predicted to introduce a frameshift and premature stop codon leading to C-
terminal truncation of ATG5 (p.K235Rfs*4) (Table 4.1 and Fig.4.1A).  This 
mutation is notable because it has been identified in four gastric and colorectal 
tumor samples (Kang et al., 2009)(Table 4.1).  It occurs at a site containing 
seven consecutive adenine nucleotides, which suggests the deletion may be a 
result of microsatellite instability (MSI) (Kang et al., 2009). 
We have previously shown that removal of either the N or C-terminus from 
ATG5 by alternative splicing prevented its interaction with and stabilization by 
ATG16L1.  This resulted in proteasomal turnover of ATG5 and prevented 
conjugation to ATG12 (Fig. 3.6, p.76).  However, many of these nonsense and 
deletion mutations affect very small portions of the N or C-terminus, so it was 
unclear if these small deletions were sufficient to impact the ATG16L1 interaction 
(Fig. 4.1A).  To experimentally test the effects of these mutations we stably 
expressed the predicted ATG5 proteins encoded by each mutation in DU145 
PCa cells and examined their abilities to conjugate to ATG12 and form a 
functional ATG12–ATG5-ATG16L1 complex (Fig. 4.1B).  Strikingly, every 
nonsense and deletion mutant failed to conjugate with ATG12 and was 
completely degraded by the proteasome, as determined by rescue with MG132.  
Even p.W12_F13delinsC, which affects only two residues within the N-terminal 
α1-helix domain, was rapidly degraded  Turnover of the ATG5 mutants coincided 
with the proteasomal degradation of ATG12 and ATG16L1 and the complete 
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inactivation of autophagy as determined LC3 lipid-conjugation and p62 
degradation (Fig. 4.1B). 
These data confirm that all of the cancer-derived ATG5 nonsense and 
deletion mutations identified to date, are amorphic or null mutations (Table 4.1).  
Moreover, we have convincingly shown that fully intact ATG5 N and C-termini are 
absolutely essential for conjugation to ATG12.  Even very small perturbations in 
these regions disrupt the stabilizing interaction with ATG16L1 and lead to 
ubiquitination and complete turnover of the complex subunits. 
 
4.2.3 Several cancer-associated ATG5 missense mutations disrupt ATG12 
conjugation and formation of the ATG12–ATG5-ATG16L1 complex.  The 
majority of ATG5 mutations identified in various tumor samples are missense 
mutations (Table 4.1).  Generally, at first glance, they do not cluster to specific 
regions of ATG5 and can be found across all domains, implying that many could 
be passenger mutations that have no effect on ATG5 function (Fig. 4.2A).  
However, we have previously identified specific residues in the N-terminal α1-
helix domain and both UFDs that are essential for ATG5 stability and conjugation 
to ATG12 (Fig. 3.7, p.80); therefore, it is difficult to predict the effects of many of 
these mutations with any certainty. 
To experimentally test the effects of these ATG5 missense mutations in 
cells, we stably expressed each of them, individually, in DU145 cells in order to 
determine their abilities to form functional ATG12–ATG5-ATG16L1 complexes 
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A.
B.
Figure 4.2 – Several ATG5 missense mutations identified in human tumor samples are 
amorphic or hypomorphic mutations.  (A) ATG5 missense mutations identified in human tumor 
samples are indicated on the ATG5 domain structure diagram.  Highlighted in yellow are those that 
dramatically reduce or eliminate ATG12 conjugation.  (B and C) DU145 PCa cells expressing an 
empty vector (EV), wild-type (WT) ATG5 or mutant ATG5 were treated with DMSO or MG132.  
Lysates were prepared and immunoblotted for ATG proteins.  The E230K mutation disrupts ATG5 
antibody recognition; however, ATG12 conjugation is still readily detected with the ATG12 antibody.
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(Fig. 4.2B and 4.2C).  Many of the missense mutations had no discernable effect 
on ATG12 conjugation or complex formation (Fig. 4.2B).  However, several 
mutations, marked in yellow, dramatically reduced or completely blocked ATG12 
conjugation and formation of a functional complex based on p62 degradation and 
LC3 lipidation (Fig. 4.2C).  Interestingly, the two mutations that completely 
disrupted all ATG12–ATG5-ATG16L1 complex activity, as determined by LC3 
conjugation, mapped to same region we had previously identified as being critical 
for ATG16L1 interaction using structure-directed mutations (colored in magenta) 
(Fig. 4.3A).  Therefore, its highly likely these mutations disrupt ATG5 interaction 
with ATG16L1, resulting in ATG5 ubiquitination and turnover, rather than 
conjugation to ATG12.  The remaining three mutations with significant effects on 
ATG12 conjugation affected proline residues located towards the core of the 
protein and not directly on the surface within the previously characterized 
ATG16L1-binding region (Fig. 4.3A).  Their surprisingly drastic effect on ATG12 
conjugation may be due to an induced conformational change that disrupts the 
sensitive ATG16L1-binding residues at the N or C-terminus.  Interestingly, the 
three proline mutations nearly, but not completely, eliminated ATG12 
conjugation, yet following treatment with MG132, they had little impact on LC3 
conjugation compared to wild-type ATG5 (Fig. 4.2C, lanes 4, 6, 10 and 18).  This 
may indicate very little ATG12–ATG5-ATG16L1 complex is needed to efficiently 
catalyze LC3 conjugation, which has been observed in other systems (Hosokawa 
et al., 2006). 
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A.
Figure 4.3 – Cancer-associated ATG5 missense mutations that impact 
ATG12–ATG5-ATG16L1 complex formation and autophagy map to a distinct region of ATG5, 
but do not act as dominant negatives.  (A) Mutated residues that severely compromise ATG12 
conjugation are colored in yellow on the surface rendering of the ATG12–ATG5 in complex with an 
N-terminal fragment of ATG16L1.  Cancer-associated ATG5 mutations map to the same region we 
have shown to be critical for ATG16L1 binding based on structure-directed mutations (colored in 
magenta) (Fig. 3.7).  (B) DU145 cells stably expressing an empty vector (EV), FLAG-tagged 
wild-type ATG5 (WT) or FLAG-tagged ATG5 (WT) plus either HA-tagged ATG5 (H241Y) or (G242R) 
were treated with DMSO or MG132.  Lysates were prepared and immunoblotted for HA, FLAG, 
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To determine if these ATG5 mutations exhibited any dominant-negative 
effects, we stably co-expressed FLAG-tagged wild-type (WT) ATG5 with HA-
tagged H241Y or G242R mutants to see if expression of either mutant had any 
effect on wild-type ATG5 or formation of the ATG12–ATG5-ATG16L1 complex 
(Fig. 4.3B).  FLAG-tagged wild-type ATG5 readily formed an ATG12–ATG5 
conjugate, even in the presence of the HA-tagged mutant versions of ATG5.  As 
before, the HA-tagged ATG5 mutants failed to conjugate with ATG12 and instead 
were ubiquitinated and degraded by the proteasome (Fig. 4.3B).  Therefore, we 
can classify the ATG5 mutations that disrupt ATG12 conjugation as amorphic or 
hypomorphic as they do not exhibit any apparent dominant negative functions 
(Table 4.1). 
Together, we have characterized nearly all of the ATG5 mutations found in 
human tumors.  We have classified many of the mutations as amorphic or 
hypomorphic due to their disruption of the ATG16L1 interaction, which prevents 
ATG12 conjugation and results in proteasomal degradation of ATG5, ATG12 and 
ATG16L1.  The ratio of tumors with amorphic and hypomorphic ATG5 mutations, 
which impact ATG12–ATG5-ATG16L1 complex formation, compared to those 
with seemingly innocuous ATG5 mutations suggests that many of the mutations 
are, in fact, not simple passenger mutations.  Moreover, we cannot rule out the 
possibility that other ATG5 mutations may impact functions of ATG5 that are 
unrelated to autophagy.  Thus, genetic mutation may be one mechanism for 
selectively inactivating ATG5 tumor suppressive function in human cancers. 
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4.2.4 The 6q21 chromosomal locus containing ATG5 is frequently deleted 
in human PCa.  Although the ratio of ATG5 amorphic and hypomorphic 
mutations to the those with no obvious effect on ATG12 conjugation suggests 
that ATG5 is a tumor suppressor, the relatively low number of overall tumors 
containing ATG5 mutations might suggest that ATG5 is not a particularly 
important tumor suppressor.  However, genetic mutation is only one of several 
mechanisms for inactivating gene function.  Advances in genomic sequencing 
and techniques, such as CGH, have facilitated high-throughput examination of 
copy number variation and large chromosomal rearrangements.  It is now clear 
that copy number variation occurs far more frequently than other types of 
mutations, with as much as 12% of the entire genome affected (Redon et al., 
2006). 
We used the cBioPortal for Cancer Genomics to examine the frequency of 
ATG5 coding sequence mutations and copy number alterations in different TCGA 
cancer datasets (Fig. 4.4A and 4.4B).  Depending on the dataset and cancer 
type, ATG5 coding sequence mutations occur in up to ~1.5% of TCGA-
sequenced tumors.  In striking contrast, a deep loss of ATG5, which is thought to 
be indicative of a homozygous deletion, occurs in as high as 16% of TCGA-
examined tumors.  Deletion of ATG5 is particularly prominent in diffuse large B-
cell lymphoma (DLBC) and PCa TCGA datasets (Fig 4.4B). 
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Figure 4.4 – ATG5 is frequently deleted human prostate cancer.  (A) Frequency of ATG5 coding 
sequence (CDS) mutations in different tumor datasets.   (B) Frequency of ATG5 copy number 
alterations across different tumor datasets.  A deep loss is thought to correspond to a homozygous 
deletion.  Data accessed through cBioPortal (Cerami et al., Cancer Discovery, 2012).
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ATG5 is located on chromosome 6 at the q21 locus (Fig. 4.5A).  There is a 
long-standing association of 6q21 deletions with many types of hematological 
malignancies, including leukemias, lymphomas and myelomas (Kamada et al., 
1992; Cigudosa et al., 1998).  Only recently have chromosomal deletions been 
discovered in solid cancers, but it is now clear that 6q21 deletions are one of the 
most frequent alterations in PCa and occur in at least one allele in ~41% of 
primary PCa and ~74% of advanced PCa (Williams et al., 2014).  Given our 
discovery and characterization of the ATG5 mutation that inactivates autophagy 
in DU145 PCa cells and nothing is known about the specific role of autophagy in 
PCa, we decided to focus specifically on ATG5 expression in PCa. 
The main challenge in determining the specific effects of chromosomal 
alterations is they generally affect a large amount of genetic information, 
sometimes as much as entire chromosome arms, leading to the 
deletion/amplification of many passenger genes along with the driver gene(s) that  
directly affect tumorigenesis.  Deletions of 6q21 have been specifically 
associated with the most commonly mutated gene in PCa, SPOP, for reasons 
that are unclear (Barbieri et al., 2012).  We used cBioPortal to examine the 
TCGA prostate cancer dataset for SPOP mutations and genetic alterations of 
6q21 genes previously implicated as tumor suppressor genes for other cancer 
types (Fig. 4.5A and 4.5B).  Deep losses (or homozygous deletions) of ATG5 and 
neighboring genes occur in roughly 14% of PCa tumors in this TCGA dataset, 
many of which occur independent of SPOP mutations (Fig. 4.5B) 
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Figure 4.5 – ATG5 deletions in PCa also encompass many neighboring 6q genes.  (A) Diagram 
of the chromsome 6q21 locus.  ATG5 and other neighboring potential tumor suppressor genes are 
indicated.  (B) Mutation and CNA of the TCGA prostate cancer dataset for SPOP and associated 6q 
potential tumor suppressor genes.  Each column represents a single tumor sample.  A deep loss is 
thought to correspond to a homozygous deletion. TCGA data accessed through cBioPortal (Cerami 
et al., Cancer Discovery, 2012). Copy number loss (C) and gain (D) of ATG5 and other PCa-related 
genes across 6 PCa tumor datasets.  The Oncomine™ Platform (Life Technologies, Ann Arbor, MI) 
was used for analysis and visualization.  
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With each column representing a single tumor sample, it is clear that the 
genes in 6q21 are most often co-deleted (Fig. 4.5B), which suggests the 
deletions affect the entire 6q21 locus.  We compared the 6q21 genes to mitogen-
activated protein kinase kinase kinase 7 (MAP3K7/TAK1), which is located 
relatively close by at 6q15 and has been directly implicated as a tumor 
suppressor gene in PCa (Wu et al., 2012; Rodrigues et al., 2015) (Fig. 4.5A).  
MAP3K7 is also co-deleted with the 6q21 genes (Fig. 4.5B), indicating that 
deletions in this TCGA PCa dataset affect 6q21 along with a large portion of the 
q arm of chromosome 6.  We used The Oncomine™ Platform (Life Technologies, 
Ann Arbor, MI) for analysis and visualization of copy number loss and gain 
across 6 available PCa datasets to confirm the results from the TCGA dataset 
(Fig. 4.5C and 4.5D). Oncomine™ ranks the genes based on the significance of 
their copy number loss or gain in prostate tumor samples compared to control 
normal tissue.  It also calculates a p-value to indicate the statistical significance 
when comparing multiple datasets. 
Oncomine™ analysis indicates MAP3K7 and the potential tumor 
suppressor genes in 6q21 are all significantly deleted when compared across all 
available PCa datasets (Fig. 4.5C).  This confirms 6q deletions occur frequently 
in PCa, but they affect many potential tumor suppressor genes, any of which 
could be driver genes. 
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4.2.5 ATG5 mRNA expression is specifically downregulated in PCa.  Since 
the 6q21 deletions in PCa affect a large number of genes, we next examined 
mRNA expression of these potential driver genes within the deleted region.  
Similar to before, we used The Oncomine™ Platform to examine mRNA under 
and overexpression of ATG5 and other potential tumor suppressor genes located 
at 6q21, in addition to MAP3K7, across 15 PCa datasets (Fig. 4.6).  Surprisingly, 
despite the frequency of 6q21 deletions (Fig. 4.5B and 4.5C), mRNA expression 
of the majority of genes within the locus were either not significantly affected or 
actually overexpressed, when comparing all available PCa datasets (Fig 4.6B 
and 4.6C).  Of the genes analyzed, only MAP3K7, ATG5 and blood vessel 
epicardial substance (BVES) were significantly underexpressed across all PCa 
datasets, although several datasets did not measure BVES expression (Fig. 
4.6B).  This indicates that either the remaining genes are not expressed at all in 
normal prostate or that hemizygous deletions of 6q21, which occur in the majority 
of PCa tumors, are insufficient to significantly suppress mRNA expression.  The 
overexpression of popeye domain containing 3 (POPDC3) and prolyl 
endopeptidase (PREP) in prostate tumors indicates the remaining intact allele is 
more than capable of compensating for a hemizygous deletion.  However, this 
does not occur for MAP3K7 or ATG5 (Fig. 4.6C), which indicates that there could 
be other mechanisms for selectively downregulating these genes beyond simple 
genetic deletions. 
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Figure 4.6 – ATG5 mRNA expression is specifically downregulated in PCa.  (A) Diagram of the 
chromsome 6q21 locus.  ATG5 and other neighboring potential tumor suppressor genes are 
indicated.  (B) mRNA underexpression rankings of ATG5 and other 6q potential tumor suppressor 
genes across 15 prostate tumor datasets.  (C) mRNA overexpression rankings of ATG5 and other 
6q potential tumor suppressor genes across 15 prostate tumor datasets.  The Oncomine™ Platform 
(Life Technologies, Ann Arbor, MI) was used for analysis and visualization.
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One mechanism could be transcriptional repression of ATG5, which was 
shown to occur in human melanomas and was thought to result from ATG5 
promoter hypermethylation (Liu et al., 2013a).  Therefore, in addition to the 
frequent genetic deletions, ATG5 and MAP3K7 may be epigenetically 
downregulated in PCa through a similar transcriptional mechanism.  The fact that 
the mRNA expression levels of the majority of the analyzed genes remain 
unchanged in PCa, despite the high frequency of copy number loss, highlights 
the potential tumor suppressive functions of those genes that are selectively 
downregulated through other mechanisms, such as ATG5 and MAP3K7. 
 
4.2.6 ATG5 is more significantly underexpressed in human PCa than many 
well-established PCa tumor suppressor genes.  The frequency of ATG5 
deletion and the corresponding selective underexpression of ATG5 mRNA in 
PCa, combined with our demonstrated effects of ATG5 nonsense, deletion and 
missense mutations, strongly implicates ATG5 as a tumor suppressor gene.  We 
also used The Oncomine™ Platform to compare ATG5 copy number and mRNA 
expression with other well-established PCa tumor suppressor genes (Fig. 4.7).  
In agreement with other meta-analyses of PCa (Williams et al., 2014), 6q 
deletions encompassing ATG5 and MAP3K7 are some of the most frequent 
alterations in PCa along with deletions of the PCa-related tumor suppressors: 
NK3 homeobox 1 (NKX3-1), TP53, RB1, PTEN and CDKN1B (p27) (Fig. 4.7A).  
Shockingly, however, the frequent genetic deletions did not strongly correlate
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Figure 4.7 – ATG5 is strongly underexpressed even compared to known PCa-related tumor 
suppressor genes.  (A) Copy number loss of ATG5 and other PCa-related genes across 6 PCa 
tumor datasets.  (B) Copy number gain of ATG5 and other PCa-related genes across 6 PCa tumor 
datasets.  (C) mRNA underexpression rankings of ATG5 and other known PCa-related genes across 
15 prostate tumor datasets.  (D) mRNA overrexpression rankings of ATG5 and other known 
PCa-related genes across 15 prostate tumor datasets.  The Oncomine™ Platform (Life Technologies, 
Ann Arbor, MI) was used for analysis and visualization.
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with the mRNA underexpression data for many of these supposedly well-
established PCa tumor suppressor genes, again likely indicating compensation 
from the remaining allele (Fig. 4.7C).  MAP3K7 and ATG5 were the most 
significantly underexpressed genes out of all the analyzed PCa-related genes, 
followed by PTEN and RB1.  This was a very unexpected finding and further 
stressed the likely importance of both MAP3K7 and ATG5 in the suppression of 
PCa. 
 
4.2.7 ATG5 and downstream ATG genes are significantly underexpressed 
in human PCa.  The frequency of ATG5 deletion and the degree to which it is 
underexpressed compared to other established tumor suppressor genes strongly 
suggests it functions as a tumor suppressor.  Still, it was not clear if this putative 
tumor suppressor function was related to autophagy.  To partially address this 
question, we examined other autophagy-related (ATG) genes that have been 
implicated as  
tumor suppressors, including BECN1 (Beclin 1), UV radiation resistance 
associated gene (UVRAG), and SH3-domain GRB2-like endophilin B1 
(SH3GLB1/Bif-1) (Qu et al., 2003; Yue et al., 2003; Liang et al., 2006; Takahashi 
et al., 2007).  Using the cBioPortal to analyze the TCGA PCa dataset for 
mutation and copy number alterations of ATG5, BECN1, UVRAG and SH3GLB1 
indicated that in PCa, ATG5 is far more frequently deleted than the other 
proposed autophagy-related tumor suppressor genes (Fig. 4.8A). 
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Figure 4.8 – ATG5 and LC3 family members are selectively downregulated in PCa.  (A) 
Mutation and CNA of TCGA prostate cancer dataset for autophagy-related (ATG) genes.  Each 
column represents a single tumor sample.  A deep loss is thought to correspond to a homozygous 
deletion.  TCGA data accessed through cBioPortal (Cerami et al., Cancer Discovery, 2012).  (B) 
mRNA underexpression and (C) overexpression rankings of ATG5 and other ATG genes across 15 
prostate tumor datasets.  The Oncomine™ Platform (Life Technologies, Ann Arbor, MI) was used for 
analysis and visualization.
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To determine if copy number correlated with mRNA expression, we 
examined under and overexpression of ATG5 and all other autophagy-related 
genes in PCa (Fig. 4.8B and 4.8C).  SH3GLB1 (Bif-1) is significantly 
underexpressed, which given the relative infrequency of its genetic deletion, is 
likely due to epigenetic repression or some other mechanism (Fig. 4.8B).  
However, SH3GLB1 also stimulates BCL2-associaed X protein (BAX) and 
promotes apoptosis (Etxebarria et al., 2009), which means its underexpression 
may not be specifically related to its function in autophagy.  Interestingly, a few 
other autophagy-related genes were significantly downregulated in PCa, almost 
all of which are LC3 family members (GABARAPL1, GABARAPL3, MAP1LC3B, 
MAP1LC3A).  The ATG12–ATG5-ATG16L1 complex is believed to catalyze the 
lipid conjugation of all LC3 family members, which means these strongly 
underexpressed genes function directly downstream of ATG5, which is also 
strongly underexpressed (Fig. 4.8B). 
The fact that several genes in the same pathway are significantly 
underexpressed and only a single autophagy-related gene was mildly 
overexpressed (Fig. 4.8B and 4.8C), suggests autophagy plays a role in prostate 
tumor suppression.  In the previous chapter, we demonstrated that there is no 
genetic redundancy for ATG5 function and that its absence leads to the loss of 
several other ATG proteins, including ATG12, ATG16L1 and ULK1 complex 
subunits.  This suggests ATG5 may be preferentially and specifically targeted by 
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several different mechanisms, all of which inactivate autophagy and its potential 
tumor suppressive function. 
 
4.2.8 ATG5 is even further underexpressed in PCa metastases.  We have 
shown that ATG5 is more strongly underexpressed than many well-established 
tumor suppressor genes in primary prostate tumors.  However, characterization 
of advanced prostate cancers and metastases indicates that genetic alterations 
of these well-established genes is predominantly a late event in prostate tumor 
progression and is not often seen in earlier stage primary tumors (Taylor et al., 
2010; Baca et al., 2013).  The accumulation of these later stage lesions, 
including amplification of androgen receptor (AR) and deletion of PTEN, are 
strongly associated with poor clinical outcomes (Barbieri and Tomlins, 2014).  
Therefore, the extent of deletion and underexpression of ATG5 in primary 
prostate tumors may be overstating its importance for PCa progression and, 
ultimately, for patient survival. 
To determine if ATG5 is similarly underexpressed in PCa metastases, we 
used The Oncomine™ Platform to examine mRNA under and overexpression for 
ATG5 and other known PCa tumor suppressor genes in 11 publicly available 
datasets that compare PCa metastases to primary tumors (Fig. 4.9A and 4.9B).  
As expected, PTEN is the most significantly underexpressed gene out of the 
analyzed genes, while AR is the second most significantly overexpressed.  
SMAD family member 4 (SMAD4) is also strongly underexpressed in human PCa 
	   119	  
  
%
151025
Not measured
Figure 4.9 – ATG5 is further downregulated in PCa metastases compared to primary tumors.  
(A) mRNA underexpression rankings of ATG5 and other known PCa-related genes across 11 
prostate metastasis datasets.  (B) mRNA overrexpression rankings of ATG5 and other known 
PCa-related genes across 11 prostate metastasis datasets.  The Oncomine™ Platform (Life 
Technologies, Ann Arbor, MI) was used for analysis and visualization.
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metastases (Fig. 4.9A), which is consistent with the finding that genetic deletion 
of Smad4 in a Pten-null mouse prostate induced invasive and metastatic PCa 
with 100% penetrance (Ding et al., 2011).  Encouragingly, ATG5 is similarly 
underexpressed in PCa metastases (Fig. 4.9A).  This suggests ATG5 functions 
as a tumor suppressor in both early and late stages of PCa. 
 
4.2.9 ATG5 suppresses DU145 PCa xenograft tumor growth.  The human 
copy number and mRNA expression data, together with our characterization of 
ATG5 mutations, all strongly suggested that ATG5 is a prostate tumor 
suppressor gene that functions both early and late in tumor progression.  
However, we had not directly tested its function in any type of cancer model.  To 
experimentally confirm its tumor suppressive function, we injected ATG5-
deficient DU145 PCa cells and those re-expressing ATG5 into NOD/SCID 
immunocompromised mice.  These mice have the severe combined 
immunodeficiency (scid) mutation in the protein kinase, DNA-activated, catalytic 
polypeptide (Prkdc) gene on an inbred non-obese diabetic (NOD) background.  
The Prkdcscid impairs B-, T- and natural killer cell function allowing 
xenotransplation. 
DU145 cells have several advantages that make them an ideal model for 
examining the tumor suppressive function of ATG5.  Firstly, we have confirmed 
DU145 cells are completely deficient in ATG5.  This is an important aspect since 
it appears that very low amounts of the ATG12–ATG5 conjugate are sufficient to 
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promote some LC3 lipid conjugation in response to prolonged proteasome 
inhibition (Fig. 4.3B, lanes 5 and 6).  Indeed, even an excellent ATG5 knockdown 
did not completely prevent LC3 lipidation in PC-3 PCa cells (Fig. 3.2C, p.62).  
Secondly, we have determined that re-expression of ATG5 is sufficient to fully 
rescue functional ATG12–ATG5-ATG16L1 complex formation and autophagy as 
determined by LC3 lipidation and p62 degradation (Fig. 3.3A, p.66).  Finally, 
even though ATG5 is technically being “overexpressed” in DU145 cells, we have 
already demonstrated that the levels of unconjugated ATG5 and the ATG12–
ATG5-ATG16L1 complex are strictly dependent upon the expression levels of 
endogenous ATG12 and ATG16L1 (Fig. 3.3B, p.66).  Therefore, the complex 
levels are self-regulated to near-endogenous levels and are not overexpressed, 
permitting the examination of “physiological” levels of ATG5 expression. 
 We first stably infected DU145 PCa cells expressing an empty vector (EV) 
or FLAG-ATG5 with a lentivirus containing firefly luciferase.  Luciferase 
expression allowed us to use the IVIS Spectrum in vivo imaging system to track 
tumor growth as a function of luciferase activity.  We initially tested whether 
ATG5 expression affected normal growth of these cells in culture, but did not find 
any difference in proliferation rates (Fig. 4.10A).  We then injected DU145 or 
DU145 FLAG-ATG5 cells subcutaneously into the flanks of NOD/SCID mice and 
monitored tumor growth weekly by measuring luciferase activity with the IVIS 
Spectrum.  Remarkably, stable expression of FLAG-ATG5 drastically suppressed 
DU145 xenograft tumor growth (Fig. 4.10B).  After seven weeks, the mice were 
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Figure 4.10 – Rescue of ATG5 in DU145 PCa cells did not affect proliferation in culture, but 
dramatically suppressed xenograft tumor growth.  (A) 1x104 DU145 PCa cells, stably 
expressing firefly luciferase and an empty vector (EV) or FLAG-ATG5, were plated in duplicate into 
6-well plates.  Total cell numbers were quantified daily by flow cytometry for 5 days.  (B) 1x104 
DU145 PCa cells stably expressing firefly luciferase and an empty vector (EV) or FLAG-ATG5 were 
injected subcutaneously into the flanks of NOD/SCID mice.  Xenograft tumor growth was determined 
by weekly measurements of luciferase activity using the IVIS Spectrum in vivo imaging system.  
Mice were sacrificed and the tumors from empty vector (EV) and FLAG-ATG5-expressing DU145 
xenografts were harvested, (C) weighed, and (D) photographed.  (E) Lysates were prepared from 
EV (lanes 1-4) and FLAG-ATG5 expressing tumors (lanes 5-8) and immunoblotted for the 
ATG12–ATG5-ATG16L1 complex and p62.
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sacrificed and the xenograft tumors were harvested, weighed and imaged, which 
confirmed the IVIS luciferase activity data (Fig. 4.10C and 4.10D).  We prepared 
protein lysates from the harvested tumors and immunoblotted them for the ATG5, 
ATG12 and ATG16L1 to confirm the tumors expressed the ATG12–ATG5-
ATG16L1 complex (Fig. 4.10E).  ATG5-expressing tumors had significantly lower 
levels of p62, which indicated that autophagy was activated and fully functional 
(Fig. 4.10E).  While this result doesn’t prove that autophagy, per se, suppressed 
tumor growth, it clearly indicates that ATG5 has tumor suppressive activity in this 
PCa xenograft model.  This result, together with the human mutation, copy 
number and mRNA expression data, strongly suggests that ATG5 is a powerful 
PCa tumor suppressor gene that is suppressed or inactivated through a variety of 
mechanisms in human cancer. 
 
4.3 Discussion 
 
 Based on our initial discovery of a splice donor-site mutation that caused 
aberrant splicing and inactivation of ATG5 in DU145 PCa cells, we set out to 
determine if ATG5 functioned as a tumor suppressor gene in human cancer.  
Other ATG5 splice region mutations have been identified in human tumor 
samples that may disrupt normal splicing and lead to proteasomal degradation of 
ATG5, ATG12, and ATG16L1.  Additionally, we have characterized ATG5 
nonsense, deletion and missense mutations, and determined many of them 
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prevent ATG12 conjugation and completely or partially inactivate ATG5.  Like 
ATG5 alternative splicing, the ATG5 nonsense and deletion mutations affect the 
N- and C-termini, both of which are essential for the ATG16L1 interaction that 
stabilizes ATG5 and promotes ATG12 conjugation.  Similarly, we have identified 
several ATG5 missense mutations, some of which are located directly at the 
ATG16L1 binding interface, and others that are found more in the core of the 
protein and may disrupt ATG16L1 interaction by inducing conformational 
changes that affect either the N- and/or C-terminus.  Thus, the unique biology of 
ATG5 and the mechanism for ATG12–ATG5-ATG16L1 complex assembly is 
such that a variety of different types of mutations all have the same functional 
effect and result in proteasomal degradation of ATG5, ATG12 and ATG16L1. 
 Even though the amorphic ATG5 mutations that prevent ATG12 
conjugation affect the ATG16L1 binding region, the absence of ATG16L1 does 
not entirely preclude ATG12 conjugation (Fig. 3.7C, p.80).  This suggests the 
mutations do more than simply disrupt ATG16L1 binding.  Since other proteins, 
including ATG16L2 and TECPR1, bind ATG5 in the same region as ATG16L1 
(Kim et al., 2015), these proteins may also stabilize ATG5 and promote ATG12 
conjugation.  More investigation is needed to determine how these ATG5 
mutations affect the functions of ATG16L2 and TECPR1.   
The ratio of amorphic or null ATG5 mutations to those mutations that have 
no apparent functional effect, suggests that inactivating ATG5 mutations may 
provide selective advantage, rather than simply existing as passenger mutations.  
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However, the frequency of ATG5 mutations in human cancer is not particularly 
high, which means ATG5 might also be inactivated through other mechanisms.  
The frequency of chromosomal deletions and rearrangements is now known to 
be far higher than single mutations, particularly in PCa (Redon et al., 2006).  We 
have confirmed previous reports indicating that prostate tumors frequently 
contain genetic deletions at the 6q21 locus on chromosome 6, which contains 
ATG5.  Surprisingly, this did not seem to affect the mRNA expression levels of 
many genes within the 6q21 locus, which could be due to compensation from the 
remaining allele.  This suggested that additional mechanisms, possibly 
epigenetic, exist for suppressing ATG5 expression in PCa.  Promoter 
hypermethylation was proposed to suppress ATG5 expression in human 
melanomas (Liu et al., 2013a).  It remains to be seen whether this is also true in 
human PCa. 
Surprisingly, ATG5 is more significantly underexpressed in PCa than 
many well-established tumor suppressor genes.  Since many genetic alterations, 
including AR amplification and PTEN deletion, occur almost exclusively in 
advanced prostate cancers (Taylor et al., 2010), we also examined ATG5 
expression in datasets comparing PCa metastases to primary tumors.  ATG5 
was also significantly underexpressed in metastases, which strongly suggests 
that ATG5 is an important tumor suppressor in late stage PCa.  This is supported 
by the fact that the DU145 PCa cell line, which we have characterized as ATG5-
deficient, was originally isolated from a brain metastasis. 
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However, this important finding does not directly agree with data from 
experimental mouse models of cancer, which suggest autophagy is required for 
tumor progression.  This may be because ATG5 functions uniquely as a tumor 
suppressor in PCa, while promoting growth of other cancer types, or it could 
simply be that the genetically engineered mouse models that have been used to 
study the effects of autophagy do not genetically approximate aggressive human 
PCa.   Autophagy has been reported to suppress tumor progression in mouse 
models of lung and pancreatic cancer driven by activating mutations in KRAS or 
BRAF.   Tumor cells with these mutations have high levels autophagy, which was 
shown to be essential for tumor cell growth in vitro and in vivo (Yang et al., 
2011).  However, unlike pancreatic and lung cancers, RAS/RAF mutations are 
rare in PCa (Grasso et al., 2012).  Therefore, ATG5 may behave differently in 
human PCa compared to mouse models of RAS/RAF-driven lung or pancreatic 
cancers due to differences in genetic backgrounds. 
These seemingly opposing findings stress the need for examining the 
role(s) of ATG5 in models of human PCa.  We compared ATG5-deficient DU145 
PCa cells to those re-expressing ATG5 in a xenograft cancer model.  We have 
fully characterized DU145 cells as being completely deficient in ATG5, which 
allowed us to cleanly assess its potential tumor suppressor function.  Expression 
of ATG5 in DU145 PCa cells dramatically suppressed xenograft tumor growth.  
We confirmed ATG5-expressing tumors had functional ATG12–ATG5-ATG16L1 
complexes and autophagy based on p62 degradation.  These results support the 
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mutational, copy number and expression data and confirm that ATG5 functions 
as a PCa tumor suppressor.  Follow up experiments are needed to determine the 
precise mechanism of tumor suppression and if it is entirely due to autophagy.  
The fact that several LC3 family member genes that function immediately 
downstream of ATG5 are also strongly underexpressed suggests that autophagy 
plays a role in ATG5 tumor suppression.  Since ATG5 expression had no effect 
on proliferation in culture, but dramatically affected xenograft growth, it suggests 
that stressors in the tumor microenvironment may play a critical factor.  Possible 
mechanisms for ATG5 tumor suppression will be discussed more thoroughly in 
the final chapter. 
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Chapter 5: Conclusions and Future Directions 
 
 Our discovery and characterization of a splice donor-site mutation that 
causes aberrant splicing of ATG5 in DU145 PCa cells is, to our knowledge, the 
first example of a genetic alteration in a human tumor or cancer cell line that has 
been proven to completely inactivate autophagy.  This discovery provided insight 
into previously unknown mechanisms of ATG12–ATG5-ATG16L1 complex 
formation and turnover.  This finding also implicated ATG5 as a tumor 
suppressor gene, which we have confirmed in a human PCa xenograft model.  
The tumor suppressive function of ATG5 was additionally supported by extensive 
mutation, copy number alteration and mRNA expression data from human tumor 
samples. Together, these results indicate that ATG5 is a highly relevant PCa 
tumor suppressor that is tightly regulated through a variety of genetic, epigenetic, 
and post-translational mechanisms.  This chapter will focus on a few of the 
interesting open questions that have arisen from these findings. 
     
5.1 Identification of genes involved in ATG12–ATG5-ATG16L1 complex 
assembly and turnover.  We have shown that free, unbound ATG5, ATG12 and 
ATG16L1 are all inherently unstable and are rapidly ubiquitinated and degraded 
by the proteasome.  However, the factors that mediate the ubiquitination and 
degradation are completely unknown.  Additionally, it’s not clear how the ATG12-
ATG5-ATG16L1 complex can be assembled if all the free, unbound subunits are 
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rapidly and continuously degraded.  Therefore, there might be unknown factors 
capable of stabilizing ATG5, ATG12 and ATG16L1 in specific contexts to 
mediate formation of the complex. To try and identify genes involved in complex 
assembly and turnover, we have developed a system that takes advantage of the 
unique instability of the complex subunits and allows for the screening of genes 
that affect turnover of ATG5, ATG12 and ATG16L1.  Since expression of ATG5 
stabilizes ATG16L1 and rescues the complex in DU145 cells, we have fused a 
fluorescent reporter to a version of ATG5 containing a mutation in the ATG16L1 
binding region, which we have previously shown prevents stabilization and leads 
to proteasomal turnover.  Therefore, the fluorescent reporter is continually 
suppressed by the ubiquitination and proteasomal degradation of its mutant 
ATG5 fusion partner.  However, treatment with a proteasome inhibitor, or 
presumably the disruption of any gene involved in mediating that degradation, 
results in the accumulation of the mutant ATG5 along with the fluorescent signal. 
On this basis, we plan to do an initial shRNA screen for E2 ubiquitin 
conjugating enzymes, of which there are approximately 40 (Komander, 2009), to 
identify which are essential for turnover of the fluorescent reporter-ATG5 fusion.  
The same principle will be applied to ATG12 and ATG16L1, since both are 
rapidly degraded in the absence of ATG5.  Since free, unbound ATG5 is normally 
completely degraded, the system allows for a wide dynamic range of signal from 
the fluorescent reporter, which should allow detection of knockdowns with only 
partial or minimal effects on turnover. 
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Another advantage of this system is that it allows the screen to be scaled 
and modified.  After the proof-of-principle E2 screen, we can use the same 
system to screen for E3 ligases, of which there are more than 600 (Komander, 
2009), and even scale up to a genome-wide shRNA or CRISPR/Cas9 screen.  
The clustered regularly interspaced short palindromic repeats (CRISPR) system 
uses guide RNAs to target CRISPR associated protein 9 (Cas9) nuclease to 
specific DNA sequences where it creates double-strand breaks that are repaired 
through error-prone DNA repair pathways and lead to gene inactivation.  Large-
scale screens will involve stable infection with a library of shRNAs or CRISPR 
guide RNAs targeting specific genes, followed by fluorescence activated cell 
sorting (FACS) for cells with positive fluorescence signal.  The specific shRNAs 
or CRISPR gRNAs that are enriched in the sorted population will be identified by 
deep sequencing and can then be confirmed in a smaller secondary screen.  
This method should identify genes directly involved in the ubiquitination and 
proteasomal degradation of ATG5, ATG12 and ATG16L1, as well as any 
upstream regulators of the process.  This should provide valuable insight into 
how ubiquitination and proteasomal degradation regulate ATG12–ATG5-
ATG16L1 complex formation. 
Importantly, the same basic principle can also be used to screen for genes 
essential for ATG12–ATG5-ATG16L1 complex assembly.  Wild-type ATG5 fused 
to a fluorescent reporter is incorporated into the ATG12–ATG5-ATG16L1 
complex providing a stable fluorescent signal.  However, disruption of the 
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complex leads to the ubiquitination and turnover of the ATG5-fluorescent reporter 
fusion.  Therefore, the screen for genes mediating or maintaining complex 
assembly would be for the loss of fluorescent signal, rather than the gain.  
Regardless, the dynamic range of the fluorescent signal should be roughly the 
same as the gain-of-fluorescence screen.  Together, these systems will serve as 
powerful tools for identifying the unknown factors involved in ATG12–ATG5-
ATG16L1 complex assembly and disassembly. 
 
5.2 Establishment of ATG5-deficient mouse models of PCa.  We have 
fully characterized ATG5 mutations identified in human tumors and found many 
of them are amorphic due to the disruption of the ATG16L1 interaction that is 
essential for ATG12 conjugation.  This suggested that ATG5 might function as a 
tumor suppressor gene.  Using publicly available tumor data, we have shown that 
ATG5 is downregulated in both primary human PCa as well as metastases.  
Along with ATG5, PTEN and SMAD4 are significantly downregulated in PCa 
metastasis, which together have been shown to suppress metastasis in mice 
(Ding et al., 2011).  Therefore, we are currently developing similar mouse models 
to test if prostate-specific Atg5 knockout promotes tumorigenesis alone and/or if 
it promotes tumor progression and metastasis in well-established mouse models 
of PCa.   
Currently, we are crossing Atg5flox/flox mice with mice expressing Cre 
recombinase under the control of the prostate-specific rat probasin (PB) promoter 
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to generate a novel prostate-specific Atg5 knockout mouse model.  These mice 
will be examined at various ages for the development of high-grade prostatic 
intraepithelial neoplasia (HGPIN), invasive adenocarcinoma and lymph node 
metastases.  This model will determine if Atg5 suppresses tumorigenesis in the 
mouse prostate.  It will also indicate if Atg5 is a haploinsufficient tumor 
suppressor gene, which has been proposed for BECN1 (Beclin 1) and AMBRA1 
(Qu et al., 2003; Yue et al., 2003; Cianfanelli et al., 2015). 
A liver-specific Atg7 knockout mouse developed benign tumors that did 
not invade or progress into malignancy, which suggested that autophagy might 
suppress tumorigenesis, while also being essential for tumor progression 
(Takamura et al., 2011).  If the prostate-specific Atg5 knockout mice develop 
HGPIN, we can determine if Atg5 suppresses or promotes progression of these 
lesions into malignant adenocarcinomas and potentially metastases.  Even if 
Atg5 deletion is insufficient on its own to generate HGPIN or adenocarcinoma, 
we also plan to cross the Atg5flox/flox mice to well-established PCa mouse models 
such as Ptenflox/flox mice.  This will allow us to determine if Atg5 deletion affects 
the development and progression of prostate tumors with predictable kinetics 
(Grabowska et al., 2014). 
These mouse models will prove if ATG5, and by extension autophagy, 
play opposing roles in PCa initiation and progression, which has been proposed 
for other cancer types (Galluzzi et al., 2015).  However, based on our human 
tumor data and our PCa xenograft results, we expect that ATG5 will be tumor 
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suppressive in both early and late stages of mouse PCa progression.  This 
prediction does not agree with the currently accepted model for the role of 
autophagy in tumor progression; however, there might be cancer-specific effects 
related to the different genetic alterations that typically occur in certain cancer 
types.  Regardless, these results will be invaluable to clinicians since the 
autophagy inhibitor, hydroxychloroquine, is currently being used in combination 
with a variety of different chemotherapies in clinical trials, including Phase 2 trials 
targeting castration-refractory and metastatic PCa (Jiang and Mizushima, 2014). 
 
5.3 Mechanistic characterization of ATG5 PCa tumor suppression.  We 
have convincingly demonstrated that ATG5 is a prostate tumor suppressor based 
on the suppression of PCa xenograft tumor growth, as well mutation, copy 
number, and mRNA expression data from human tumors.  Since copy number 
and mRNA expression levels do not necessarily correlate with protein expression 
levels, we will determine if ATG5 protein is underexpressed in human PCa by 
immunohistochemistry.  We expect that this will confirm that the multiple 
mechanisms of ATG5 downregulation ultimately lead to the loss of ATG5 protein 
levels in human PCa. 
Additionally, the exact mechanism of ATG5 tumor suppression still 
remains to be determined.  The simplest explanation is that autophagy 
suppresses tumor formation, growth and metastases.  We confirmed that the 
ATG5-expressing xenograft tumors have functional autophagy due to the 
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dramatically lower levels of the autophagy substrate, p62.  p62 is reported to 
have a number of oncogenic functions including stabilizing Twist-related protein 1 
(Twist1) and c-Myc as well as stimulating mTORC1, nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) and nuclear factor, erythroid 2-like 2 
(NRF2) signaling (Moscat and Diaz-Meco, 2012; Qiang et al., 2014; Wei et al., 
2014).  Thus, ATG5 may suppress tumor growth by facilitating autophagic 
elimination of p62.  To test this possibility, we will knock down p62 using shRNAs 
or delete it using CRISPR/Cas9 in order to determine if it attenuates xenograft 
tumor growth.  Conversely, we will stably infect ATG5-expressing DU145 cells 
with p62 containing a mutated LC3 interacting region (LIR) to prevent autophagic 
degradation.  Together these experiments will show whether p62 accumulation is 
responsible for driving tumor growth in the absence of ATG5 and autophagy. 
Since the loss of ATG5 leads to proteasomal degradation of ATG12 and 
ATG16L1, and also affects expression of the ULK1 complex, ATG5 tumor 
suppressive function could be related to any or all of these affected proteins 
rather than autophagy, per se.  Since the expression of ATG5, ATG12 and 
ATG16L1 are interdependent, it remains a challenge to isolate their individual 
functions.  Our findings regarding ATG12–ATG5-ATG16L1 complex stability 
have provided insight into how we can potentially uncouple and individually 
stabilize ATG5 and ATG16L1 to determine if the tumor suppressive function is 
dependent upon ATG16L1 or the fully assembled complex.  Since ATG5 stability 
is dependent upon its interaction with ATG16L1, we have fused the N-terminus of 
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ATG16L1 directly to ATG5 and found that it prevents binding of endogenous 
ATG16L1, and presumably ATG16L2 and TECPR1 since they all share the same 
binding site.  This results in the proteasomal turnover of endogenous ATG16L1 
and the expression of a stable, free form of ATG5.  Conversely, we have shown 
that removal of the ATG5-binding site from ATG16L1 prevents its ubiquitination 
and turnover, which is essential for stable ATG16L1 expression in the absence of 
ATG5 (Fig. 3.3D).  With these approaches we can express ATG5 and ATG16L1 
independently of one another in DU145 PCa cells to determine if either of these 
proteins alone is responsible for xenograft tumor suppression.  This should 
determine if ATG5 tumor suppression is dependent upon formation of a 
functional ATG12–ATG5-ATG16L1 complex and autophagy or through an 
alternative, non-autophagic mechanism. 
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